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Healthy eating, physical activity, stress management, and smoking cessation are widely 
recognized as essential for preventing and treating coronary artery disease (CAD). Research on 
lifestyle programs for patients with CAD has largely focused on long-term interventions (e.g., 
several months to one-year in duration). Further, many studies have recruited patients 
immediately post-cardiac event. By contrast, evaluation of brief lifestyle interventions for stable 
patients treated in outpatient cardiology is lacking. The present study evaluated the feasibility, 
acceptability, and efficacy of a 3-session behavioral health lifestyle program for patients with 
stable CAD being treated in an outpatient cardiology clinic. Thirty-three patients were 
randomized to the Intervention Group (IG) or to Treatment as Usual (TAU). Outcome measures 
were assessed at Post-treatment (two-weeks after Baseline) and at 30-day Follow-up. Reliable 
change and parametric analyses were used to evaluate study outcomes. Results indicated that the 
program was both feasible and acceptable to patients, as determined by a priori criteria: over 60 
percent of referred and eligible patients agreed to participate, over 75 percent of consented IG 
participants completed the program through 30-day Follow-up, and over 80 percent of 
participants reported that they would recommend the program to other patients. With regard to 
treatment outcomes, data from 28 participants were available. Reliable change analyses revealed 
that at both Post-treatment and 30-day Follow-up, significantly more IG than TAU participants 
exhibited an increase in self-efficacy as compared with Baseline. There were no observed 
between-group differences on other study measures, though repeated-measures ANOVAs were 
underpowered. Overall, results support the feasibility and acceptability of brief lifestyle 
interventions in outpatient cardiology care and highlight the role of behavioral health providers 
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on integrated cardiology care teams in helping to increase patient self-efficacy in managing 
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INTRODUCTION AND LITERATURE REVIEW 
Coronary Artery Disease: A Brief Overview for Clinical Health Psychologists 
Approximately one in every four deaths in the United States (U.S.) is attributable to heart 
disease (U.S. Department of Health and Human Services, 2017a). Coronary artery disease 
(CAD), also commonly referred to as coronary heart disease (CHD) or ischemic heart disease, is 
the most common form of heart disease. CAD is the cause of death for over 370,000 individuals 
in the U.S. yearly (U.S. Department of Health and Human Services, 2017a).  
 CAD is characterized by atherosclerosis and resulting complications. Atherosclerosis 
involves buildup of plaque, consisting of fatty substances such as cholesterol. This buildup 
occurs as a result of repairing repeated damage to the endothelium (lining) of arteries (Herrmann 
& Lerman, 2012). Indeed, cardiac risk factors such as high cholesterol, hypertension, diabetes, 
smoking, and older age, increase risk for coronary events in part by contributing to this process 
of endothelium damage (Herrmann & Lerman, 2012). Consistent repair of damage results in 
changes to the artery structure, including plaque growth and coronary lesions that result from 
plaque rupture and thrombosis (Wilson, 2012a). In turn, these may contribute to reduced blood 
flow and acute coronary syndromes associated with CAD, such as myocardial infarction (MI) or 
“heart attack” (Herrmann & Lerman, 2012).  
A hallmark symptom of CAD is angina, which primarily manifests as chest discomfort. 
Angina results from an imbalance in myocardial supply and demand of oxygen (Garcia & 
McFalls, 2012). Angina may present in a predictable manner (i.e., stable angina, such as when 
exercise results in a demand of oxygen that exceeds supply) or in an unpredictable manner 
(unstable angina, which is considered an acute coronary syndrome or ACS). Typical angina is 
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associated with left side, substernal chest discomfort (characteristic 1), follows from physical or 
emotional stress (characteristic 2), and is relieved with rest or nitroglycerin (a medication for 
angina; characteristic 3). Atypical angina has two of the three outlined characteristics (Garcia & 
McFalls, 2012). The annual mortality rates for stable angina are approximately one to two 
percent, and thus most patients with stable angina have a good prognosis. Those with severe left 
ventricular dysfunction and more widespread CAD are at increased risk for mortality (Garcia & 
McFalls, 2012). 
CAD may ultimately lead to an ACS (Herrmann & Lerman, 2012). ACS is associated 
with rapid increase in symptomatology or ischemia, which involves reduced blood flow (and 
therefore oxygen) to the heart (Wilson, 2012a). The term ACS encompasses a spectrum of 
unstable coronary syndromes, including but not limited to unstable angina and myocardial 
infarction or “MI” (Wilson, 2012a). The primary cause of ACS is plaque rupture within the 
arteries and subsequent clotting of the damaged area (Wilson, 2012a). Among other substances, 
lipoproteins, including LDL (“bad” cholesterol) primarily comprise of the plaque. Plaque and 
associated blood clots can reduce blood flow to the heart, and sometimes completely block the 
artery (Wilson, 2012a). Of note, there is increased risk of MI and death in the six months 
following development of ACS (Wilson, 2012a). With regard to MI, a number of complications 
may result from the infarction. The reduced blood supply and oxygen to the heart results in tissue 
damage or death. This can be associated with left ventricular failure (associated with cardiogenic 
shock and death as a result of inadequate blood supply to heart), rupture of the left ventricular 
(LV) wall, rupture of ventricular septum, ventricular arrhythmia, thromboembolism, and other 
complications depending on the characteristics of the MI (Vlodaver & Wilson, 2012). Given the 
serious nature of ACS, prompt evaluation and treatment are necessary. 
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Treatment for CAD and related acute coronary events may range from medicinal to 
surgical. Medicinal antithrombotic treatment, such as aspirin or heparin, may be initiated to treat 
any blood clots. Drugs to reduce heart rate and blood pressure (e.g., beta receptor antagonists, 
“beta blockers”) may be used as well to prevent MI. Percutaneous coronary intervention (PCI), 
or angioplasty, is a non-surgical intervention that typically involves using a balloon, guided by a 
catheter, to widen the lumen (space inside of the artery), which may be narrowed due to plaque 
and other buildup. This subsequently improves coronary flow (Wilson, 2012b). Stents may then 
be used to promote maintenance of the widened lumen. Additional medications may be utilized 
to prevent thrombosis in the coronary vessel, and other negative responses to these procedures 
(Wilson, 2012b). PCI may additionally be utilized in conjunction with thrombectomy to aspirate 
any blood clots (Wilson, 2012b).  
Coronary artery bypass grafting (CABG) is another treatment for CAD, and unlike PCI, 
is surgical in nature. It is generally indicated for higher risk CAD symptomatology (e.g., left 
main stenosis [narrowing of the artery], or triple vessel disease) or in cases with comorbid 
diabetes (Liao, 2012). The goal of treatment is to revascularize those coronary arteries with 
significant (e.g., more than 50%) of luminal narrowing (Liao, 2012). In CABG surgery, arteries 
and veins from the body are used to re-route blood flow around blocked arteries to increase 
blood flow to the heart.  
In the time before or after an ACS, a patient may be thought to be “stable,” or be 
characterized as having “stable CAD.” Interestingly, there is a lack of specification regarding at 
what point a patient is deemed “stable,” even within task force recommendations from medical 
societies such as the American Heart Association, American College of Cardiology Foundation, 
and others (Fihn et al., 2012). While research studies of “stable” CAD patients have diverse 
 4 
definitions of the population, they have commonly included specified time frames since ACS or 
revascularization. Examples of inclusion criteria include MI at least three months prior to 
enrollment (Fox et al., 2003; PEACE Trial Investigators, 2004), and CABG or percutaneous 
transluminal coronary angioplasty at least three months (PEACE Trial Investigators, 2004) or six 
months (Fox et al., 2003) prior to enrollment. Additionally, examples of exclusion criteria have 
included planned coronary revascularization (PEACE Trial Investigators, 2004; Fox et al., 2003), 
and hospitalization for unstable angina within preceding two months (PEACE Trial 
Investigators, 2004). Thus, the common aim of such criteria is to ensure that the patient is not 
experiencing, or in immediate recovery from, an acute coronary episode. However, active 
monitoring and treatment is essential even for those with “stable” CAD, as they remain at 
increased risk for cardiac events.  
Of note, management of other common chronic conditions is essential when treating 
CAD, as such conditions may be associated with independent health risks and additionally 
contribute to increased cardiovascular risk. Hypertension, for example, is experienced by nearly 
one fourth of the U.S. population and is associated with increased risk of cardiac events and 
CAD mortality (Rosendorff et al., 2015). Among other mechanisms, hypertension is associated 
with endothelial dysfunction, which may subsequently affect plaque development and facilitate 
atherosclerosis (Rosendorff et al., 2015). High cholesterol is also associated with increased 
coronary risk, as high LDL levels are associated with plaque buildup that may reduce blood flow 
and ultimately lead to ACS (U.S. Department of Health and Human Services, 2005). Further, 
patients with diabetes are at a two to four-fold increased risk of cardiovascular disease, 
highlighting the importance of treating this highly comorbid condition (Skyler et al., 2009). 
While mechanisms explaining increased cardiac risk among patients with diabetes continue to be 
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investigated, it is thought that increased coagulability (clotting ability) may partially explain 
increased risk for MI (Leon & Maddox, 2015). Obesity is likewise associated with increased 
cardiac risk factors such as hypertension, dyslipidemia (high cholesterol or fats), diabetes, and 
other disorders, and is additionally associated with increased risk of cardiovascular disease 
mortality (Jensen et al., 2014). Lastly, smoking increases CAD symptomatology by increasing 
blood clotting tendency, decreasing ability to exercise, and is related to atherosclerosis (U.S. 
Department of Health and Human Services, 2014). Thus, treatment of these and other related 
health conditions may be essential for promoting cardiac and overall health. 
 While treatment for CAD and other common comorbid conditions may involve medicinal 
and/or surgical treatment, healthy lifestyle behaviors are additionally crucial for preventing and 
managing CAD and related diseases. Modifying lifestyle behaviors has yielded critical health 
benefits for patients living with CAD. Lifestyle recommendations and associated research are 
outlined below and serve as the foundation for the current study. 
Lifestyle, Health Behaviors, and CAD: Current Recommendations 
In addition to appropriate pharmacological and medical procedure follow-up, regular 
engagement in healthy lifestyle behaviors is necessary for cardiac health. Indeed, lifestyle 
changes are particularly important among cardiac populations, as healthy eating, physical 
activity, stress management, and smoking cessation, among other areas are essential for both the 
management (e.g., Fihn et al., 2012) and prevention (e.g., Arnett et al., 2019) of cardiovascular 
disease. For stable CAD, the American College of Cardiology Foundation, American Heart 
Association, and other medical bodies include recommendations to address health behavior risk 
factors (Fihn et al., 2012). Several of these areas, pertinent to the development of the evaluated 
intervention, are outlined in this section. 
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Healthy Eating  
Healthy eating (or diet) recommendations for stable CAD may include a diet high in fresh 
fruit, whole grains, and vegetables, and low in saturated fat, trans fat, cholesterol, and sodium 
(Fihn et al., 2012). Indeed, comprehensive and validated diet plans exist to maximize heart-
healthy eating among cardiac patients. Two of the most well-known plans include the Dietary 
Approaches to Stop Hypertension (DASH) plan and the Mediterranean diet. The DASH plan 
emphasizes reducing saturated fat, total fat, cholesterol and sodium, and involves little 
consumption of red meat and food/drink with added sugar. By contrast, it emphasizes increased 
intake of fruit, vegetables, low fat dairy products, whole grains, poultry, fish and nuts (U.S. 
Department of Health and Human Services, 2003, 2006). An example of the DASH eating plan 
for an individual consuming 2,000 calories per day may include daily consumption of 6-8 
servings of grain and grain products, 4-5 servings of vegetables, 4-5 servings of fruit, 2-3 
servings of low fat or fat free dairy foods, 6 or fewer servings of lean meats, poultry, and fish, 2-
3 servings of fats and oils, in addition to 4-5 servings of nuts, seeds, and or dry beans per week 
and a maximum 5 servings of sweets per week (U.S. Department of Health and Human 
Services, 2015a). However, this plan may be adjusted based on an individual’s needs. Adherence 
to the DASH plan is associated with reduced blood pressure (Sacks et al., 2001; Vollmer et al., 
2001), and lower cholesterol levels (Harsha et al., 2004) among other health outcomes. 
Additionally, it has been shown to be associated with reduced body weight, waist circumference, 
and A1c levels among patients with diabetes (Azadbakht et al., 2011).  
Similar to the DASH plan, the Mediterranean diet emphasizes increased consumption of 
fruit, vegetables, grains, beans, and nuts. Dairy products, fish, poultry, and red wine are 
consumed in low to moderate amounts, and red meat is consumed minimally. Of note, specific 
 7 
definitions for the Mediterranean diet have varied, especially in terms of the recommended 
quantity of consumption for various food groups; however, in general, Mediterranean-style diets 
are high in monounsaturated fat (mainly olive oil) and low in saturated fat (Davis, Bryan, 
Hodgson, & Murphy, 2015). Overall, research has shown that adherence to such diets is 
associated with lower incidence of cardiovascular disease mortality (Fung et al., 2009), lower 
cardiac death and nonfatal MI, and reduced frequency of other cardiac events such as unstable 
angina, stroke, heart failure, and pulmonary or peripheral embolism (de Lorgeril et al., 1999). It 
is also associated with reduced all-cause, CVD, and cancer mortality in the U.S. population 
(Mitrou et al., 2007).  
While differences exist with regard to the DASH and Mediterranean diet plans, both 
emphasize increased consumption of fruit, vegetables, whole-grains, beans, and nuts, in addition 
to regular consumption of poultry and fish. Both eating patterns also limit saturated fat. Indeed, it 
is unsurprising that diets emphasizing reduced saturated fat and trans fat have been associated 
with positive health outcomes, as this may help to manage lipid levels that contribute to 
atherosclerosis and plaque buildup. Specifically, for cardiac health it is recommended to limit 
saturated fat to no more than six percent of total calories, trans fat to less than one percent of 
total calories, and cholesterol to less than 200 mg/day (Fihn et al., 2012). In addition, limiting 
sodium (consistent with the DASH plan) may reduce blood pressure (Fihn et al., 2012). 
Specifically, reducing to no more than 2,300 or 2,400 mg of sodium per day is recommended for 
cardiac health, and lowering to 1,500 mg/day can further help lower blood pressure (Eckel et al., 
2014, U.S. Department of Health and Human Services, 2006). Reducing by 1,000 mg/day, even 
if the resulting outcome is above recommended limits, may still yield benefits (Eckel et al., 
2014). Of course, other comorbid medical conditions such as diabetes may further inform diet 
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recommendations (e.g., reduced carbohydrates). Healthy eating recommendations for the 
proposed intervention follow AHA guidelines and DASH guidelines and are additionally largely 
consistent with aspects of the Mediterranean diet that are shared with DASH (e.g., a diet high in 
fruit, whole grains, and vegetables, and low in saturated fat). 
Physical Activity  
Physical activity recommendations for stable CAD include engagement in 30-60 minutes 
of moderate intensity aerobic activity, such as brisk walking, at least five days per week (Fihn et 
al., 2012). There is also evidence that resistance training two days per week may yield benefits, 
such as improvements in quality of life and physical strength (Fihn et al., 2012). For at-risk 
patients at first diagnosis, cardiac rehabilitation and home-based programs that are physician-
directed are recommended. Risk assessment with an exercise test and/or physical activity history 
is also recommended for patients more generally (Fihn et al., 2012) 
Among patients with CAD, exercise-based cardiac rehabilitation is associated with 
reduced mortality (Taylor et al., 2004). One meta-analysis found 20% reduced risk of all-cause 
mortality and 26% reduced risk of cardiac mortality among those who participated in cardiac 
rehabilitation versus usual care, highlighting the importance of exercise in this population 
(Taylor et al., 2004). Physical activity may improve cardiac health through a variety of 
mechanisms. For example, it is associated with lower rates of LDL, blood pressure, and diabetes, 
in addition to better weight management (Eckel et al., 2014, Lichtenstein, et al., 2006). In these 
ways, physical activity may lower clinical risk factors for CAD and cardiac events. Additionally, 
relevant biological pathways for improved cardiac functioning may also include improved 
endothelial function and collateralization, which may help improve blood supply to the heart 
(Heaps & Parker, 2011; Newcomer, Thijssen, & Green, 2011). For this reason, it is unsurprising 
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that walking programs emphasizing regular engagement in moderate aerobic exercise have 
yielded beneficial results (Coke & Fletcher, 2010; Lau, Thompson, Burr, & Dougherty, 2016; 
Faulkner, Gerhard, Stoner & Lambrick, 2012; Nemoto, Hirokazu, Masuki, Okazaki, & Nose, 
2007.). For example, one study found that after engaging in a 6-month walking program 
(walking three times per week), participating individuals with myocardial ischemia experienced 
increased exercise capacity and reduced diastolic blood pressure reactivity compared with 
control individuals (Neumann, Brown, Waldstein, & Katzel, 2006).  
Stress Management 
Risk factor modification for patients with stable CAD includes management of 
psychological factors. Patients with stable CAD report high levels of stress, and stress is 
associated with increased cardiac events (Rosengren et al., 2004). Therefore, unsurprisingly, 
stress management is a component of many cardiac rehabilitation programs. Both behavioral and 
physiological mechanisms may account for the link between stress levels and CAD risk. For 
individuals experiencing depression, behavioral mechanisms may include reduced healthy 
behaviors such as medical adherence, healthy diet, and regular exercise, (Fihn et al., 2012). 
Physiological mechanisms linking stress and increased CAD risk may include effects from 
repeated activation of the sympathetic nervous system (Krantz, Whittaker, & Sheps, 2012). 
While rigorous work is needed in this area, directions for additional research include cardiac 
autonomic dysfunction, impaired endothelial functioning, low-grade inflammation, platelet 
hyperactivity, increased coagulation, among others (Carney & Freedland, 2009; Davison, 
Alcántara, & Miller, 2018; Poole, Dickens, & Steptoe, 2011). Acute stress and other negative 
emotions such as anger may also lead to increased risk for cardiac events (Krantz et al., 2012). 
Therefore, it is critical to manage both acute and chronic stress.  
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Among patients with CAD, screening for and treating depression in particular may be an 
important part of treatment. Estimates suggest that approximately 20% of patients with CHD 
meet criteria for a depressive disorder immediately post MI (Bush et al., 2005; Thombs et al., 
2005). While there are fewer studies on the persistence of depression in this population, research 
suggests that it may persist for many patients (Thombs et al., 2005). Depression is associated 
with increased risk for MI and cardiac events more generally; one meta-analysis indicated that 
depressed individuals were 1.3 times as likely as non-depressed individuals to experience any 
CHD event, and 1.3 times as likely to experience MI (Gan et al., 2014). Unsurprisingly, for 
stable CAD patients, the American College of Cardiology Foundation, American Heart 
Association, and other medical bodies indicate that it is reasonable to screen patients for 
depression and refer to treatment when needed (Fihn et al., 2012). 
While research regarding the link between anxiety and CAD is less well studied than that 
of depression and CAD, several recent meta-analyses have demonstrated anxiety to be associated 
with increased cardiac risk. For example, one meta-analysis found elevated anxiety symptoms to 
be associated with 41% increased risk of cardiovascular mortality, 41% increased risk of 
coronary heart disease, and 35% increased risk of heart failure (Emdin et al., 2016). Another 
found anxiety symptoms to be associated with 48% increased risk of cardiac death in cohorts of 
initially healthy individuals (Roest, Martens, de Jonge, & Denollet, 2010). Further, individuals 
experiencing chronic stress experience increased cardiac risk (Davison et al. 2018; Rozanski, 
2014). Therefore, individuals demonstrating symptoms related to negative affect more generally, 
whether this manifests primarily depressive symptoms, anxious symptoms, or other negative 
emotions, may be good candidates for stress management interventions. Such interventions often 
include a combination of relaxation techniques, cognitive techniques, and behavioral techniques 
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(Fihn et al., 2012). Stress management interventions have been associated with positive physical 
and psychological outcomes among those with stable CAD more generally. Additional 
information on results of such interventions is described in the “Lifestyle Interventions and 
CAD” section below. While the present study discusses stress and its relation to CAD, it is also 
important to note that other cardiac conditions such as heart failure and arrhythmias are 
associated with psychological distress that may necessitate intervention (Dornelas & Sears, 
2018). 
Smoking Cessation 
Tobacco use is the leading cause of preventable death, disease, and disability in the U.S., 
and thus is critical for improved health (U.S. Department of Health and Human Services, 2019). 
For patients with stable CAD, it is recommended that providers encourage smoking cessation 
and avoidance of exposure to second-hand tobacco smoke. Subsequent follow-up and treatment 
is recommended for smoking cessation, which may include behavioral and pharmacological 
interventions (Fihn et al., 2012). 
With regard to cardiac health, smoking is associated with increased atherosclerosis, 
increased blood clotting, and increased risk for stroke (U.S. Department of Health and Human 
Services, 2014). Heavy smokers (e.g., over 25 cigarettes/day) may be 5.5 times as likely to 
experience fatal CAD than nonsmokers, and 5.8 times as likely to experience non-fatal MI 
(Willet et al., 1987). Biological mechanisms linking smoking to cardiovascular health include 
impacts on vasomotor dysfunction, inflammation, modification of lipid profiles, and thrombosis 
risk factors, among others (Ambrose & Barura, 2004). While cigarette smoking is clearly 
associated with increased cardiac risk, smoking cessation can yield important health benefits in a 
relatively short time frame. Reduced risk of heart attack and improved lung functioning may 
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occur in as little as two weeks to three months of quitting (U.S. Department of Health and 
Human Services, 1990; U.S. Department of Health and Human Services, 2004). Further, 
smoking cessation yields important improvements in cardiac health. For example, one study 
found that current male smokers younger than the age of 55 were 2.9 times more likely than non-
smokers to experience MI, but the risk after two to three years of abstention was comparable to 
never-smokers (Rosenberg, Kaufman, Helmrich, & Shapiro, 1985). A meta-analysis also found 
36% risk reduction of mortality for patients with CHD who quit smoking versus those who did 
not, among studies with various evaluation timelines (Critchley & Capewell, 2003). Such studies 
highlight the importance of smoking cessation among those with stable CAD.  
Thus, engagement in healthy lifestyle behaviors is essential in maintaining overall and 
cardiac-specific health. Evaluation of research interventions targeting such behaviors for cardiac 
patients is outlined next.  
Lifestyle Interventions and CAD 
 Interventions developed to improve lifestyle and health behaviors among patients with 
CAD have had diverse foci, with various emphases on diet, physical activity, and stress 
management, among other areas. Intervention lengths, specifics of the research population (e.g., 
women, individuals with elevated depressive symptoms), and outcome measures have varied as 
well, and thus, it is unsurprising that research in this broad area has yielded variable results. 
Overall, study results have been very promising for psychological variables, and more mixed for 
physical cardiac risk marker and cardiac event variables. However, a few key studies have 
yielded very positive results for improving physical health via lifestyle intervention, encouraging 
additional research in this area. 
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There have been several very successful, long-term, comprehensive lifestyle 
interventions for improving health among patients with CAD. For example, one randomized 
controlled study evaluated an intervention which included education and behavioral modification 
components related to diet, exercise, psychological factors, and smoking behavior for patients 
with coronary disease and recent history of PCI (Lisspers et al., 1999). The intervention began 
with a four-week residential stay, including group and individual sessions, and continued in 
outpatient format for the duration of a year. At the end of treatment, the intervention group 
demonstrated increases in exercise frequency and diet knowledge and a decrease in weight 
compared with the control group. No differences were observed for psychological factors or 
clinical events (Lisspers et al., 1999).  
Another comprehensive, year-long program with a focus on diet (low fat, whole foods, 
plant-based; no more than 10% of calories from fat), moderate exercise (three or more hours per 
week), stress management (at least one hour per day of activities such as stretching, progressive 
relaxation, breathing techniques, and/or visualization), and social support (group sessions twice 
per week) demonstrated improvements in cardiac-related health behaviors such as diet, exercise, 
and stress management, in addition to quality of life over the course of the one-year follow-up 
(Billings, 2000; Koertge, et al., 2003). Additionally, there was a significant decrease in physical 
risk for cardiac events (e.g., lower plasma lipids, blood pressure, weight, and higher exercise 
capacity; Koertge et al., 2003). In an earlier five-year trial investigating similar treatment 
components, the intervention group experienced significant decrease in angina at one and five-
years post-study initiation (91% reduction at year one, and 72% reduction at year five) versus the 
control group (186% increase at year 1, 36% decrease at year 5- in part due to revascularization). 
Patients in the intervention group also experienced decreased stenosis after both one and five 
 14 
years, versus increased stenosis observed in the control group at both time points. Additionally, 
the intervention group experienced fewer cardiac events (MI, angioplasty, CABG, cardiac 
hospitalizations, cardiac-related death) during the 5-year follow-up (control group 2.47 times as 
likely as experimental group to experience any cardiac event; Ornish et al., 1998).  
With regard to interventions with a primarily psychological focus, a recent review and 
meta-analysis found that while psychological interventions were associated with reduced 
psychological symptoms (small/moderate effect) and reduced cardiac mortality (small effect), 
they were not associated with total mortality, subsequent revascularization, or non-fatal MI 
(Whalley, Thompson, & Taylor, 2014). These results are similar to earlier reviews demonstrating 
modest effects for reducing psychological distress, and small or non-existent effects for cardiac 
mortality, total mortality, revascularization, and non-fatal MI (e.g., Rees, Bennett, West, Smith, 
& Ebrahim, 2004). However, several studies, such as The Stockholm Women’s Intervention 
Trial for Coronary Heart Disease (SWITCHD), serve as excellent illustrations of how stress 
reduction programs may have beneficial effects for cardiac patients. In this study, women with 
history of MI, CABG, or PCI, occurring approximately four months prior to intervention 
commencement, were recruited for a 20-session group stress management intervention lasting 
approximately one year. The intervention focused on risk factor education, cognitive 
restructuring, relaxation techniques, coping, and self-care (Orth-Gomér et al., 2009). Over the 
course of the intervention and follow-up (end of follow-up was, on average, 7-years post-
randomization), 7% of women in the intervention group died vs. 20% in usual care (Orth-Gomér 
et al., 2009). While exact mechanisms of action are unknown, this study illustrates the strong 
impact that a psychological intervention may have on mortality for individuals with coronary 
disease. In a similar study, individuals who engaged in a CBT program with a focus on stress 
 15 
management (20, two-hour sessions over the course of one year) experienced 45% fewer 
recurrent acute MIs compared to treatment as usual during the follow-up period (mean=94 
months; Gulliksson et al., 2011).  
In another study, Blumenthal and colleagues evaluated the effects of adding stress 
management with a focus on CBT principles (12 weekly, 1.5-hour group sessions) to cardiac 
rehabilitation training. The authors described cardiac rehabilitation training as largely consisting 
of aerobic exercise, three times per week, utilizing 70-85% of heart rate reserve, in addition to 
general education about CHD and nutritional guidelines, with two classes devoted to stress 
management. Individuals in the intervention group demonstrated reduced stress levels after 
treatment, in addition to lower rates of clinical events such as all-cause mortality, fatal or non-
fatal MI, stroke/TIA, unstable angina requiring hospitalization, or coronary or peripheral artery 
revascularization (18% for intervention group vs. 33% for control group) over the 5-year follow-
up period (Blumenthal et al., 2016). In an earlier study evaluating the benefit of added stress 
management training (1.5-hour group sessions for 16 weeks) vs. added exercise training 
(supervised 35 minutes of aerobic exercise training, three times per week for 16 weeks) to usual 
care for those with CAD, improvements in depression for both intervention groups vs. usual care 
were observed. Additionally, clinical variables such as left ventricular ejection fraction (LVEF) 
during mental stress testing and flow-mediated dilation were improved for intervention group 
participants vs. control individuals. (Blumenthal et al., 2005).  
 As suggested by the results of aforementioned meta-analyses (i.e., Rees et al., 2004; 
Whalley et al., 2014), not all psychological intervention studies have yielded anticipated benefits 
for cardiac patients. For example, one intervention for female patients with CAD demonstrated 
no benefit for clinical risk markers (e.g., waist circumference, high sensitive C-reactive protein, 
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fibrinogen) among individuals participating in a 20-session, group-format, year-long CBT stress 
management program versus those in usual care (Claesson et al., 2006). Similarly, another 
comprehensive intervention, the Enhancing Recovery in Coronary Heart Disease (ENRICHD) 
study, evaluated psychological intervention (maximum of six months CBT-focused treatment, 
sertraline added as adjunct as needed) for those with depression and/or low perceived social 
support. In this study, there were no observed difference between individuals who were in the 
intervention vs. the control group in terms of mortality (Carney et al., 2004). However, 
improvements in depressive symptoms and low social support were observed for patients 
receiving the intervention (Berkman et al., 2003), and follow-up analyses revealed reduced 
cardiac mortality and nonfatal MI for white men only (Schneiderman et al., 2004). Additionally, 
a year-long CBT group intervention for female cardiac patients, focusing on psychological 
variables specifically, found no differences between intervention group individuals and control 
group individuals in terms of depressive symptoms (Koertge et al., 2007). Such results prompt 
further investigation of factors related to intervention success. For example, it could be that stress 
management interventions are most helpful when the program additionally includes other 
lifestyle modifications such as diet and exercise, as such interventions are often associated with 
reduced physical risk markers such as atherosclerotic burden (Jhamnani et al., 2015). 
Comprehensive risk reduction programs are not limited to clinical research trials. 
Engagement in cardiac rehabilitation programs are recommended by AHA and the American 
College of Cardiology Foundation for individuals with ACS and for individuals immediately 
post PCI or CABG (Smith et al., 2011). These programs offer a multifaceted approach for 
improving cardiac health. Programs may include a focus on healthy behaviors such as lifestyle 
and exercise, nutritional and psychosocial counseling, and medication management, among other 
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services (Balady et al, 2011). These programs are associated with improvements on cardiac risk 
factors and reduced mortality (Balady et al., 2011). However, less than 40% of heart attack 
survivors and less than 40% of patients who receive CABG participate in cardiac rehabilitation 
(Balady et al., 2011). Lack of accessibility, lack of insurance coverage, and lack of referral 
(particularly for women and ethnic minorities) contribute to low attendance rates (Balady et al., 
2011). Given the high prevalence of and adverse health consequences associated with CAD, it is 
essential to offer clinical services that are feasible and acceptable for both patients and clinics to 
facilitate usage.  
A potential avenue through which to increase accessibility and acceptability of services to 
patients and providers is via brief treatment protocols, within the patient centered medical home. 
In this context, brief treatment may reduce temporal or financial barriers for patients, and thus 
translate into increased attendance and health gains. Fortunately, there have been several 
promising studies demonstrating effectiveness of brief (approximately one to seven sessions in 
length) behavioral health treatment for cardiac patients (e.g., Black et al., 1998; Mayou et al. 
2002; McLaughlin et al., 2005). Results of these studies are encouraging, with evidence of 
decreased depression (Black et al., 1998), improvements in quality of life (Mayou et al. 2002), 
and reduced anxiety and functional limitation (McLaughlin et al., 2005). However, these studies 
have often been conducted only with those with elevated psychological distress (e.g., 
McLaughlin et al., 2005) or in a hospital setting (e.g., Mayou et al. 2002). Additional research is 
needed regarding efficacy of brief interventions in outpatient cardiac care for those both with and 
without elevated psychological distress. 
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Present Study 
The present study evaluates the feasibility, acceptability, and efficacy of a brief behavioral 
health intervention program aimed at addressing lifestyle behaviors for patients with stable CAD 
in outpatient cardiology care. Results from longer interventions suggest that lifestyle 
interventions may be very effective in addressing psychological and physical factors related to 
cardiac health, and results from previous brief studies in hospital settings and with populations 
experiencing psychological distress are promising. Importantly, patients often receive lifestyle 
intervention and related information after an ACS, and indeed, recruitment for previous lifestyle 
studies has largely been from hospital settings. The present intervention was designed for 
implementation in outpatient cardiac care, to be accessible to a wide range of patients with stable 
CAD status— including those without history or with distant history of ACS and/or 
hospitalization. Thus, this research addresses a critical gap in the literature for a population at 
risk for cardiac morbidity and mortality. The brief nature is intended to increase feasibility and 
acceptability to both clinics and patients, and implementation in the patient’s cardiac clinic 
increases accessibility for both patients and providers. This also helps address a recognized need 
for developing integrated behavioral health into specialty cardiac clinics (Dornelas & Sears, 
2018). Results of this study are intended to inform future development of interventions for brief 
secondary prevention in outpatient cardiology care. 
Feasibility and Acceptability  
A focus of feasibility and acceptability is critical in intervention development to help 
inform program changes that will allow for successful implementation and impact on patient 
care. In general, feasibility studies, or pilot studies, can be used to evaluate and inform 
recruitment, study procedures, program implementation and refinement, and more (Leon, Davis, 
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& Kraemer, 2011). Importantly, it is essential to establish a priori criteria with which to deem a 
program feasible or acceptable (Jones, Olds, Currow, & Williams, 2017). A priori criteria for 
feasibility and acceptability for the present study included: 
Feasibility 
1) At least 60% of referred and eligible patients agree to participate (Horton et al., 2013) 
2) At least 75% of the consented intervention group patients complete the study 
intervention and outcome measurements through 30-day follow-up (Horton et al., 
2013) 
Acceptability 
1) At least 80% respond “Yes” to the Yes/No question at post-treatment: “Would you 
recommend this intervention to other patients with coronary artery disease?” (Jones et 
al., 2017).  
Efficacy 
While efficacy is not typically a main focus of studies evaluating feasibility and 
acceptability (Eldridge et al., 2016; Leon et al., 2011), preliminary tests of efficacy were 
conducted for the purpose of informing future development of this and similar programs.  
Primary tests of effectiveness included investigation of study effects with regard to: 
1) Patient confidence in managing cardiac disease, as indicated by perceived self-
efficacy and illness perceptions. 
 Hypothesis 1: Participants in the Intervention Group (IG) will report 
greater self-efficacy in managing disease over time as compared with 
participants in the Treatment as Usual (TAU) group. 
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 Hypothesis 2: Participants in the IG will report less threatening illness 
perceptions over time as compared with participants in the TAU group.  
2) Psychological outcomes as indicated by depressive and anxious symptoms. 
 Hypothesis 3: Participants in the IG will report greater decreases in 
depressive symptomatology over time as compared with participants in the 
TAU group. 
 Hypothesis 4: Participants in the IG will report greater decreases in 
anxious symptomatology over time as compared with participants in the 
TAU group. 
Secondary tests of effectiveness included evaluation of how the proposed intervention 
may increase preparedness to engage in healthy eating and physical activity. These tests were 
considered exploratory given that modules differentially emphasized certain lifestyle behaviors, 
and that participants only completed two out of five potential modules. 
 Hypothesis 5: Participants in the IG will report greater self-efficacy for 
both healthy eating and physical activity, in addition to greater 
engagement in these behaviors over time, as compared with participants in 
the TAU group.  
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RESEARCH DESIGN AND METHODOLOGY 
Participants and Recruitment 
Participants 
Participants included patients with stable CAD, being treated by a board-certified 
cardiologist at a college of medicine outpatient faculty practice. The clinic is a patient-centered 
medical home (PCMH) with over 15 specialties. For the present study, stable CAD was defined 
as: 
1) CAD as indicated by history of at least one MI, at least one coronary 
artery bypass graft surgery, at least one coronary stent, and/or at least 
one coronary vessel with stenosis > 70%. 
2) Stable status as indicated by no MI, unstable angina, or ACS within 
the past three months, no coronary revascularizations within the past 
three months, and no planned revascularizations. 
Exclusion criteria include: 
1) Age < 30 years or > 79 years 
2) Women who are pregnant or breast feeding 
3) Non-English-speaking 
4) Participation in another clinical trial concurrently or within 30 days 
before screening 
5) Cognitive impairment as indicated by diagnosis in medical chart 
6) Psychotic symptoms as indicated by diagnosis in medical chart 
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7) Current treatment for non-skin malignancy, malignant melanoma, or 
advanced kidney disease (indicated by stage 4 or 5 or on dialysis) 
8) Psychological safety concerns, including plans to harm oneself within 
the past two months and/or suicide attempt within the past year 
9) Ejection fraction < 30% 
10) Physician determination of inappropriateness for study, due to 
anticipated life expectancy of <1 year, presence of a survival limiting 
or uncontrolled illness, and/or hemodynamically important valvular 
disease. 
Adults unable to consent, individuals who were not yet adults (infants, children, 
teenagers), pregnant women, and prisoners were also not eligible for the study. 
Recruitment 
 Individuals were identified for study inclusion criteria via medical chart review and 
patient interaction during regularly scheduled medical appointments with the cardiologist. 
Interested individuals then spoke with the graduate research assistant to complete study 
screening, and to complete the consent process if desired. At times, individuals indicated interest 
in the study, but did not have time to review the consent form on the day of their office visit.  In 
such cases, an alternate time was scheduled to complete the consent process at the patient’s 
convenience, to ensure ample time for all patient questions to be answered. 
Study Procedures 
Study protocol was reviewed and approved by the Institutional Review Board (see 
Appendix A) and HIPAA Compliance Officer. Data storage followed clinic IT Security 
guidelines.  
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The study consisted of two research groups: the Intervention Group (IG) and Treatment 
as Usual (TAU). Both groups completed the informed consent process and signed a HIPAA 
release form to facilitate release of PHI from the PCMH to the research team. Then, participants 
were randomly assigned to each group via a random number generator, and participants had an 
equal chance of being assigned to either group. The principle investigator generated the random 
allocation sequence, enrolled participants, and assigned participants to the interventions. Thus, 
this trial was an unblinded, randomized design.  
After completing the consent and randomization process, participants scheduled their 
Baseline appointments at their earliest convenience. Baseline appointments consisted of 
completing an intake (Cardiac Research Questionnaire, see Appendix B) and questionnaires. 
After Baseline, IG participants participated in a 3-session lifestyle program lasting approximately 
two weeks, and then completed a 30-day follow-up. By contrast, TAU participants completed a 
Baseline appointment, 2-week follow-up appointment, and a 30-day follow-up appointment. 
Upon completing this participation period (lasting approximately six weeks), TAU participants 
were then offered the option to participate in the lifestyle program. Additional information is 
provided in the “Study Protocol” section below. 
Study Protocol 
Intervention Group (IG) 
IG participants participated in the lifestyle program, titled “CLIMB” (Cardiac Lifestyle 
Intervention for Maintaining Healthy Behaviors). CLIMB consisted of three sessions. During the 
first session, participants completed a baseline assessment consisting of a cardiac research 
questionnaire (Appendix B) and psychosocial questionnaires. Then, participants immediately 
(same day) completed Session 1. During Session 1, participants received feedback regarding 
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their Baseline questionnaire responses, completed a values exercise to elicit engagement, and 
identified motivations for change. They also selected preferred modules for Sessions 2 and 3 
(one module for each session), from a choice of five modules. This format allowed for selection 
of material most relevant to the participant and is similar in format to a recent effective 
intervention for patients with heart failure or chronic obstructive pulmonary disease (Cully et al., 
2017). Session 1 ended with the participant making a behavioral goal for the next session. 
During Sessions 2 and 3, material relevant to the elective modules (one module per session) was 
reviewed and relevant behavioral goals were made for each session. At the end of Session 3, 
participants completed post-intervention questionnaires. Questionnaires were additionally 
administered at 30-day follow-up.  
Elective modules topics include “Healthy Eating,” “Physical Activity,” “Reducing Stress 
and Worry,” “Mood Management” and “Smoking Cessation Education.” Each participant who 
participated in the “Physical Activity” module received clearance from the cardiologist to do so. 
Common elements among modules included review of the behavioral goal from the previous 
session, psychoeducation, identifying and problem-solving barriers to performing relevant health 
behaviors, and making behavioral goals. Elective module descriptions can be found in Appendix 
C. Module topics were included based on research regarding the importance of targeting healthy 
eating, physical activity, psychological factors, and smoking cessation to improve health for 
patients with stable CAD. While weight management is another important topic for cardiac 
health, low-intensity (fewer than or equal to five sessions) weight management interventions 
have not translated into clinically meaningful weight loss for patients (U.S. Department of 
Health and Human Services, 2013). Given the brief nature of the intervention, a weight 
management module was not selected for the evaluated program. However, patients interested in 
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weight management activities were encouraged in modules that seemed most relevant to their 
weight management needs (e.g. “Healthy Eating”). 
 The timeline for IG participation included: 
1) Baseline assessment: Approximately one hour (Baseline questionnaires 
completed) 
2) Session 1: Approximately one hour, immediately following Baseline (same-
day) 
3) Session 2: Approximately one hour, one week following Session 1 
4) Session 3: Approximately 1.5 hours, one week following Session 2 (Post-
treatment questionnaires completed) 
5) 30-day follow-up: Approximately one hour, 30 days following Session 3 (30-
day follow-up questionnaires completed) 
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Figure 1. Group participation timelines 
 
Treatment as Usual (TAU)  
The TAU group continued to receive their usual medical care while they completed 
research questionnaires over the course of approximately six weeks. The TAU group filled out 
study questionnaires at time points comparable to the IG: at Baseline, at 2-week follow-up (two 
weeks after Baseline), and at 30-day follow-up (30 days after the 2-week follow-up). After this 
point, they were given the option to participate in the CLIMB program. Participation timelines 
for IG and TAU participations are displayed in Figure 1. 
Telephone Contact  
For IG participants, Baseline and Session 1 always occurred at the PCMH. For 
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scheduled session within one calendar week after the specified session date (e.g., for 
Session 2 within 14 days of Session 1) or within three business days prior to the specified 
time point, then participants had the option to participate by telephone. For the TAU 
group, the Baseline session always occurred at the PCMH. Participants were permitted to 
complete 2-week and 30-day follow-up data either in-person or by telephone. 
Study Data  
Study data was stored on Health IT encrypted file shares. Only research team members 
had access to these files. Psychosocial questionnaires were administered using Qualtrics and 
associated with ID number only. Upon completion of the study, participants had the option to 
request a summary of their research participation to be released to the PCMH and included in 
their medical records. This included information regarding their participation attendance, 
research module selection, engagement, and any referrals that were requested during the study. 
Measures 
Participants, in collaboration with the research team member, completed the cardiac 
research intake form. This contained demographic and clinical information relevant for the 
lifestyle program.  
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Feasibility and Acceptability 
Attendance and Eligibility Screening Records  
Attendance and eligibility screening records were used to evaluate a priori feasibility 
criteria.  
Program Development Questionnaire.  
This measure was created by the research team to evaluate participant reactions to 
different components of the program, and to elicit feedback more generally to inform future 
refinement of the intervention. This measure was administered at Post-treatment to IG 
participants. The Program Development Questionnaire is included in Appendix D.  
Satisfaction with Care Questionnaire 
This measure was created by the research team to evaluate satisfaction with the provided 
intervention. Item 4 on the measure (“Would you recommend this intervention to other patients 
with coronary artery disease?”) was used to evaluate the a priori criteria for acceptability. This 
measure was administered at Post-treatment to IG participants. The Satisfaction with Care 
Questionnaire is included in Appendix E. 
Efficacy Outcomes: Primary  
Self-Efficacy for Managing Chronic Disease Scale (SEMCD-6) 
The SEMCD-6 is a six-item measure of self-efficacy for managing chronic illness. Each 
item is scored on a Likert scale of 1-10, with higher scores indicating greater levels of self-
efficacy. The overall score has a high internal consistency (Cronbach’s alpha = .88-.91), and 
evidence suggests that the scale is one-dimensional in structure (Lorig, Sobel, Ritter, Laurent, & 
Hobbs, 2001; Ritter & Lorig, 2014). The total score is the mean of the six items. This measure 
has been used in other brief interventions for patients with cardiopulmonary conditions (e.g., 
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Hundt et al., 2018). Importantly, self-efficacy is shown to be a predictor of health behavior 
change (see Sheeran et al., 2016 for meta-analysis). 
Brief Illness Perception Questionnaire (BIPQ) 
The BIPQ is a nine-item measure evaluating overall patient perceptions of illness 
(Broadbent, Petrie, Main, & Weinman, 2006). The measure is a shortened form of the longer 
Illness Perceptions Questionnaire-Revised (IPQ-R; Moss-Morris et al., 2002). Each BIPQ item 
refers to a different domain of illness perceptions (Leventhal et al., 1997; Leventhal, Brissette, & 
Leventhal, 2003). Examples include: perceived control of illness, emotional reaction to illness, 
and understanding of illness. The first eight items are scored on a Likert scale of 0-10, and items 
3, 4, and 7 are reverse-scored. The ninth item is an open-ended question regarding perceived 
causes of illnesses and was not used in the present study. Scores on the first eight items may be 
summed for a total score, with higher scores representing more threatening views of illness. Test-
retest reliability of individual items (one through eight) over a six-week period ranges from .61-
.75, with the exceptions of one item (personal control, r = .42) (Broadbent et al., 2006). Test-
retest reliability of a Dutch translation indicates good test-retest reliability of the total score (ICC 
= .72; Hallegraef, van der Schans, Krijnen, & de Greef, 2013). Evaluations of various 
translations of the BIPQ also suggest good internal consistency for the total score: r = .74 for 
Polish translation (Nowicka-Saur et al., 2015) and r = .73 for the Dutch translation (Hallegraef et 
al., 2013). Research has demonstrated that less threatening illness perceptions among cardiac 
patients are associated with better quality of life (e.g., Janssen, de Gucht, van Exel, & Maes, 
2013). Additionally, one study found that individuals receiving an intervention to address illness 
perceptions after MI returned to work sooner and reported less angina than other individuals—
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illustrating the importance of evaluating illness perceptions among patients with cardiac disease 
(Petrie, Cameron, Ellis, Buick, & Weinman, 2002). 
Patient Health Questionnaire-9 (PHQ-9) 
The PHQ-9 is a brief self-report measure of depressive symptoms (Kroenke, Spitzer, & 
Williams, 2001). The questionnaire consists of 9 items, with each item representing a different 
depressive symptom. Item scores represent frequency with which symptoms are present, ranging 
from 0 (not at all) to 3 (nearly every day). Psychometric analysis of the PHQ-9 demonstrates 
strong criterion and construct validity and internal consistency with a Cronbach’s alpha of .83-
.92 (Cameron, Crawford, Lawton, & Reid, 2008; Kroenke et al., 2001). Summed scores of 0-4 
are considered minimal depressive symptoms, scores of 5-9 are considered mild depressive 
symptoms, scores of 10-14 are considered moderate depressive symptoms, scores of 15-19 are 
considered moderately severe depressive symptoms, and scores of 20-27 are considered severe 
depressive symptoms (Kroenke et al., 2001).  
Generalized Anxiety Disoder-7 (GAD-7).  
The GAD-7 is a brief self-report measure of anxious symptoms (Spitzer, Kroenke, 
Williams, & Löwe, 2006). The questionnaire consists of 7 items and is a screening measure for 
anxious symptoms typically experienced by those with generalized anxiety disorder. Item scores 
represent frequency of the experienced symptoms, ranging from 0 (not at all) to 3 (nearly every 
day). Psychometric analysis of the GAD-7 demonstrates good internal consistency among both 
primary care and general populations, test re-rest reliability (ICC = .83), and criterion and 
construct validity (Löwe et al., 2008; Spitzer et al., 2006). Summed scores of 0-4 suggest 
minimal anxious symptoms, scores of 5-9 suggest mild anxious symptoms, scores of 10-15 
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suggest moderate anxious symptoms, and scores of 15-21 indicate severe anxious symptoms 
(Spitzer et al., 2006).  
Efficacy Outcomes: Secondary 
Starting the Conversation (STC) 
 STC is a brief and validated dietary assessment designed for health promotion 
settings (Paxton, Strycker, Toobert, Ammerman, & Glasgow, 2011). It is a broad, 8-item 
food frequency questionnaire assessing overall dietary patterns. A summary score may be 
computed by summing all 8 items, with higher scores generally reflecting greater room 
for dietary improvement. Test-retest reliability is established over a four-month period (r 
= 0.66). The summary score has demonstrated convergent validity with the National 
Cancer Institute (NCI) fat screener (r = 0.39). In the present study, participants were 
asked to consider their food intake patterns over the past two weeks when making their 
response selections (changed from “over the past few months” in the original measure, 
due to the short-term nature of the study). 
Global Physical Activity Questionnaire (GPAQ) 
 The GPAQ is a measure of physical activity recommended by the World Health 
Organization (WHO). The GPAQ measures physical activity behavior at work (including 
housework), during travel, and during recreational activities. The measure can be scored 
in a variety of ways, yielding continuous indicators (e.g., MET-minutes/week, time spent 
in physical activity, minutes spent sitting), or by categorical indicators (e.g., whether one 
has met a recommended guideline for physical activity levels; World Health 
Organization, n.d.). A comprehensive psychometric evaluation revealed overall good 
test-retest reliability across various ways of scoring the measure, as well as concurrent 
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validity with other physical activity measures (Bull, Maslin, & Armstrong, 2009). For the 
present study, a summary score of moderate and physical activity across domains (work, 
travel, recreation) per day was utilized, consistent with other studies (e.g., Herrmann, 
Heumann, Der Ananian, & Ainsowrth, 2013). 
Smoking Cessation Measures 
 Smoking behavior was assessed for participants who reported having smoked a 
cigarette over the past month. Smoking was assessed via patient self-report of number of 
cigarettes per week over the past two weeks. Attitudes towards change were measured 
using three motivation rulers scored from 0-10 (“How important is stopping smoking to 
you?” “How ready are you to quit smoking within the next month?” “How confident are 
you that you will quit smoking within the next month?”). Use of such rulers has 
demonstrated good convergent validity with other stages of change measures in addition 
to smoking behavior (Boudreaux et al., 2012). Participants were also asked if they would 
like a referral facilitated to aid in smoking cessation. 
Dieter’s Inventory of Eating Temptations-Self-Efficacy (DIET-SE) 
 The DIET-SE is a scenario-based, self-report measure of self-efficacy in adhering 
to healthy eating in a variety of situations (Stich, Knäuper, & Tint, 2009). Psychometric 
properties of the total score are established (test-retest reliability: r = .83; internal 
consistency: a = .82). The measure also demonstrates appropriate convergent validity 
with related measures (Stich et al., 2009). Further, there are three available subscales 
related to common challenges in adhering to healthy eating patterns: high caloric food 
temptations, social and internal factors, and negative emotional events. Internal 
consistency for the three subscales ranges from a = .77 to a = .79, and test-re-test 
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reliability ranges from r = .75 to r = .80 (Stich et al., 2009). The measure is slightly 
modified for the current study by changing the term “boyfriend or girlfriend” in one item 
to “significant other” to increase inclusiveness. The present study utilized the total score 
of the scale, which is calculated by summing responses across all items. 
Exercise Confidence Survey (ECS) 
 The ECS is a 12-item measure of exercise self-efficacy. Each item is scored on a 
1-5 Likert scale, with greater scores indicating greater levels of confidence. The measure 
is adapted (one-item difference) from the original Exercise Self-Efficacy and Exercise 
Habits Survey (Sallis, Pinski, Grossman, Patterson, & Nader, 1988). The updated scale 
replaced the item “Get up earlier to exercise” (similar to another item on the survey: “Get 
up early, even on weekends, to exercise”) with “Attend a party only after exercising.” 
Test-retest reliability of the revised measure over a one-week period is established: ICC = 
.78 (Sallis, n.d.).  
Statistical Methodology 
Feasibility and acceptability criteria as outlined above were evaluated descriptively via 
attendance records (feasibility) and responses to the question “Would you recommend this 
intervention to other patients with coronary artery disease?” (acceptability). With regard to 
efficacy, a series of four repeated-measures ANOVAs (dependent variables: SEMCD-6, BIPQ, 
PHQ-9, and GAD-7) were computed to evaluate main hypotheses related to efficacy. Reliable 
change index scores were also calculated (Jacobson and Truax, 1991; Johnson, Dow, Lynch, & 
Herrmann, 2006). Secondary efficacy outcomes were analyzed using the same statistical 
procedures for the following variables: STC, GPAQ, DIET-SE and the ECS. Smoking variable 
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analyses were omitted because no participants smoked a cigarette within the past month at the 





Participants were recruited over the course of nine consecutive months in 2018 and 2019. 
Every patient with stable CAD presenting to the cardiology clinic during recruitment days 
throughout this period was evaluated for study eligibility. As outlined in the CONSORT diagram 
(Figure 2), data from 28 participants were available for efficacy analyses. Of the 33 consented 
participants, five were excluded from efficacy analyses: two IG and one TAU participant 
dropped out prior to Baseline appointment, one IG participant was withdrawn by the research 
team after Baseline/Session 1 due to ACS, and one IG participant was excluded due to 
participation in another lifestyle program with similar intervention targets (e.g., dietary and stress 
management changes, setting SMART goals). Thus, data from the latter two participants were 




Figure 2. Consort flow diagram 
Included in efficacy analysis (n=14) 
Excluded from efficacy analysis (n=2) 
 Withdrawn by research team after 
Baseline/Session 1 (n=1) 
 Enrolled in additional lifestyle program with 
overlapping content (n=1) 
 
Included in efficacy analysis (n=14) 
Excluded from efficacy analysis (n=0) 
 
Analysis 
Allocated to Intervention Group (n=18) 
 Received allocated intervention (n=16) 
 Did not receive allocated intervention (n=2) 
o Participants dropped out prior to 
intervention baseline (n=2) 
 
Allocated to Treatment as Usual Group (n=15) 
 Received allocated sessions (n=14) 
 Did not receive allocated sessions (n=1) 









Lost to follow-up (n=0) 
Discontinued intervention (n=1) 
 Withdrawn by research team after 
Baseline/Session 1 due to discovered ACS 
Lost to follow-up (n=0) 
Discontinued participation (n=1) 





 Not meeting inclusion criteria (n=30) 
 Declined to participate (n=15) 
 Lost to follow-up before consent (n=4) 
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Feasibility and Acceptability 
Feasibility 
Study recruitment and attendance records were examined to identify if the following a 
priori feasibility criteria were met: 
1) At least 60% of referred and eligible patients agree to participate  
2) At least 75% of the consented Intervention Group patients complete the study 
intervention and outcome measurements through 30-day follow-up  
Thirty-three out of fifty-two (63.5%) of referred and eligible patients agreed and 
consented to participation, indicating that that the first study feasibility criteria was met. Patients 
declined for the following reasons: work schedule (n=7), already making lifestyle changes (n=2) 
upcoming medical procedures or appointments (n=2), lived out of state (n=1), family obligations 
(n=1), and not reported (n=2). Additionally, four patients indicated interest in the study, but 
were lost to follow-up prior to consent.  
Fifteen out of eighteen (83.3%) consented IG patients completed the study intervention 
and outcome measures through 30-day follow-up, indicating that the second feasibility criteria 
was also met. For the three participants who did not complete the intervention and measures 
through 30-day follow-up, two had dropped out of the study prior to starting the CLIMB 
program (i.e., after consent, but before Baseline/Session 1), whereas one was withdrawn by the 
research team after the Baseline/Session 1 appointment due to discovered ACS. Therefore, with 
the exception of one participant, all those who started CLIMB completed the entirety of the 
program. 
Sixteen IG participants completed Session 1, and therefore engaged in module selection. 
“Healthy Eating” was the module most often selected, followed by “Mood Management” and 
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“Reducing Stress and Worry” (See Figure 3 for more information). Of note, none of the 
participants selected the Smoking Cessation Module, as none had smoked a cigarette within the 
past month at the time of their Baseline appointment. Additionally, three IG individuals had not 
been cleared for the Physical Activity module, and thus interest in this module may have been 
greater than reflected in the numbers above. The average session duration for the modules were 
as follows: 62 minutes for “Healthy Eating”, 51 minutes for “Physical Activity”, 64 minutes for 
“Reducing Stress and Worry” and 59 minutes for “Mood Management.”  
Participants had the option to complete certain research meetings by phone. For IG 
participants, a total of two participants completed at least one research meeting remotely: one 
person completed 30-day follow-up questionnaires by phone, and the other completed post-
treatment questionnaires by phone. For TAU participants, a total of two individuals completed at 
least one research meeting remotely: both completed 2-week follow-up questionnaires by phone. 




Figure 3. CLIMB module selection 
Acceptability 
Answers to the following question were evaluated to determine if the a priori 
acceptability criterion was met: 
1) At least 80% respond “Yes” to the Yes/No question at post-treatment: “Would you 
recommend this intervention to other patients with coronary artery disease?”  
Fifteen out of 15 (100%) of IG participants who completed post-study questionnaires 
responded “Yes” to this question, indicating that the a priori acceptability criterion was met. 
Efficacy 
Participant Characteristics 
Demographic characteristics of IG and TAU participants included in efficacy analyses 
(N=28) are outlined in Table 1, and clinical characteristics and baseline medications are outlined 









Healthy Eating Physical Activity Reducing Stress
and Worry


















self-report. Information displayed in Tables 2 and 3 was obtained via medical record, with the 
exception of the following items from Table 2 which were obtained via self-report: cardiac 
rehabilitation history, psychiatric history (depression and anxiety), and tobacco use. With regard 
to substance use, participants were characterized as “Never Smokers” if they had smoked fewer 
than 100 cigarettes in their lifetimes, “Former Smokers” if they had smoked 100+ cigarettes in 
their lifetimes but none in the past month, and “Current Smokers” if they had smoked at least one 
cigarette within the past month (U.S. Department of Health and Human Services, 2017b). All 
participants with a history of heart failure were compensated at the time of study enrollment. 
Between-group differences were evaluated using chi-square and Fisher’s exact test for 
categorical variables, and t-tests for continuous variables. With regard to demographic variables, 
TAU participants were significantly younger than IG participants, t(26) = 2.535, p = .018. There 
were no significant differences with regard to clinical variables. Information for consented 
participants not included in efficacy analyses is displayed in Table 4.  
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(n = 28) 
Intervention Group 
(n = 14) 
Treatment as Usual 
(n = 14) 
Gender    
   Male 











Marital Status    
   Married 
   Divorced 
   Single 
   Separated 

















Race    
   Caucasian/White 
   Latino/a 
   Asian 
   African American/Black 
   Native American 




















Highest Level of Education    
   Graduate Degree 
   Bachelor’s Degree 
   Associate’s Degree 














Employment Status    
   Retired   
   Employed 
   Part-time employment   
   Unemployed 
















*p < .05 for differences between Intervention Group and Treatment as Usual participants 
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(n = 28) 
Intervention Group 
(n = 14) 
Treatment as Usual 
(n = 14) 
BMIa M(SD) 29.46 (4.72) 28.76 (3.71) 30.10 (5.56) 
H/O ACS    
   Yes 







Current Stable Angina    
   Yes 







H/O Heart Failure    
   No 
   Yes- Preserved LVEF 










H/O Revascularization    
   Stents 
     Yes 
     No 
   CABG 
     Yes 



















H/O Cardiac Rehabilitation    
   Yes 







Hypertension    
   Yes 







Diabetes    
   Type 2 
   Type 1 










Dyslipidemia    
   Yes 







H/O Depression (Treatment 
or Diagnosis) 
   
   Current 
   Past 










H/O Anxiety (Treatment or 
Diagnosis) 
   
   Current 
   Past 










Tobacco Use    
   Smoker 
   Former Smoker 










Note. H/O = history of; BMI = body mass index; ACS = acute coronary syndrome; LVEF = left ventricular ejection 
fraction; CABG = coronary artery bypass grafting 
aExcludes the missing BMI data for one intervention group participant  
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(n = 28) 
Intervention Group 
(n = 14) 
Treatment as Usual 
(n = 14) 
Aspirin/Other Anti-Platelet    
   Yes 







Beta Blockers    
   Yes 







Calcium Channel Blockers    
   Yes 







ACE inhibitors and/or ARB 
inhibitors 
   
   Yes 









   
   Yes 







Anti-coagulants    
   Yes 







Anti-diabetes    
   Yes 







Diuretics    
   Yes 








Of note, examination of ACS and revascularization history reveals long-term stability 
among many study participants. Twenty-five out of 28 participants had a history of 
revascularization (i.e., CABG and/or stents). Of these individuals, the average time since last 
coronary revascularization was 5.64 years (SD = 5.32). Only two of the 25 (8.0%) had their most 
recent revascularization within the twelve months prior to study enrollment. Fourteen of the 28 
(50.0%) had a history of ACS. Of these fourteen, the average time since last ACS was 7.01 years 




Table 4. Characteristics of Participants Not Included in Efficacy Analyses 
Participant Group Age Gender Reason 
A IG 70 M Dropped out before Baseline 
appointment 
B IG 73 M Dropped out before Baseline 
appointment 
C IG 78 M Withdrawn before collection of 
post-treatment data due to ACS 
D IG 68 M Enrolled in additional lifestyle 
program with overlapping content 




 Missing data were evaluated for each group across time points. Data were evaluated for 
complete missing data on questionnaires (i.e., no responses) and partial missing data on 
questionnaires (i.e., incomplete responses). Of note, one TAU participant did not complete Time 
3 questionnaires. With the exception of this participant, all missing ECS data (total and partial) 
was as a result of marking “N/A” to one or multiple items (treated as missing data), rather than 
leaving responses blank. Regarding complete missing data on questionnaires, group- and time-
specific means were utilized to impute total scores (for example, if the ECS total score was 
missing from an IG participant at Time 2, then the mean score of IG participants at Time 2 was 
utilized as replacement). Using this method, one TAU participant had ECS total score data 
imputed at Time 2, and one TAU participant had total scores for all questionnaires imputed at 
Time 3 (participant dropped out before Time 3)—these were the only two participants with 
missing data for an entire questionnaire at any time point.  
Regarding partially filled out measures, the SEMCD-6 and ECS were the only 
questionnaires for which participants submitted incomplete responses. Both measures were 
calculated by taking an average of the items completed by each participant, and thus individual 
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items were not imputed. For the SEMCD-6, three individuals had partial missing data for at least 
one time point (i.e., missing at least one item-level response). Missing responses ranged from 2-3 
items per individual at any given time point. For the ECS, twenty-one individuals had partial 
missing data for at least one time point (i.e., an “N/A” response on at least one time point). 
Partial missing data ranged from 1-7 missing items for an individual at any given time point.  
 Outliers were evaluated within each group at each time point utilizing an absolute value 
z-score cut-off of 3.29 (Field, 2013; Tabachnick & Fidell, 2013). No univariate outliers were 
identified. Normality was evaluated by Zskewness (skew/SEskew) and Zkurtosis (kurtosis/SEkurtosis), 
with values > 3.29 considered non-normal (Tabachnick & Fidell, 2013). Total scores from the 
GPAQ, SEMCD-6 and PHQ-9 were non-normal for at least one time point. Therefore, 
transformations were attempted to reduce skew and kurtosis. A square root transformation for the 
GPAQ total score, a reflect and square root transformation for the SEMCD-6 total score, and a 
log transformation for the PHQ-9 total score all resulted in normal transformed variables 
(Tabachnick & Fidell, 2013). Therefore, these three transformed variables were utilized in 
respective ANOVA analyses. Untransformed variables were utilized for reliable change 
analyses.  
Descriptive Statistics 
Following data cleaning, descriptive statistics were performed on untransformed baseline 
responses for the eight efficacy outcome variables, with results displayed in Table 5. There were 
no differences observed between groups on these variables, as assessed by t-tests for normal 
baseline variables (SEMCD-6, BIPQ, GAD-7, STC, DIET-SE, ECS) and Mann Whitney-U tests 
for non-normal baseline variables (PHQ-9, GPAQ). There were also no significant differences 
for the transformed baseline SEMCD-6, PHQ-9, and GPAQ variables. At Baseline, all 
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participants in both groups reported that they had not smoked a cigarette within the past month. 
Means and standard deviations for dependent variables at all time points are displayed in 
Appendix F. 
Table 5. Baseline Descriptive Statistics for 2 (Group) X 3 (Time) ANOVAs 
 
Measure 
Total Sample (n = 28) 
 M (SD) 
Intervention Group (n = 14)  
M (SD) 
Treatment as Usual (n = 14) 
M (SD) 
SEMCD-6 7.64 (1.68) 7.21 (2.16) 8.07 (.90) 
BIPQ 31.86 (10.36) 30.79 (10.70) 32.93 (10.28) 
PHQ-9 3.04 (4.21) 3.21 (4.61) 2.86 (3.94) 
GAD-7 3.00 (2.54) 3.07 (2.37) 2.93 (2.79) 
STC 5.32 (2.28) 5.64 (2.68) 5.00 (1.84) 
DIET-SE 28.50 (7.63) 25.79 (6.34) 31.21 (8.06) 
GPAQ 63.56 (58.57) 58.61 (57.53) 68.51 (61.34) 
ECS 3.91 (.93) 3.77 (.91) 4.05 (.96) 
Note. SEMCD-6 = Self-Efficacy for Managing Chronic Disease Scale; BIPQ = Brief Illness Perception 
Questionnaire; PHQ-9 = Patient Health Questionnaire-9; GAD-7 = Generalized Anxiety Disoder-7; STC = Starting 
the Conversation; DIET-SE = Dieter’s Inventory of Eating Temptations-Self-Efficacy; GPAQ = Global Physical 
Activity Questionnaire; ECS = Exercise Confidence Survey 
 
Repeated Measures ANOVAs 
Repeated measures ANOVAs were utilized to evaluate changes over the three time 
points: Time 1 (Baseline), Time 2 (Post-Treatment [IG]/2-week follow-up [TAU]), and Time 3 
(30-day follow-up). The average time between Times 1 and 2 was 15.86 days (SD = 3.17), and 
the average time between Times 2 and 3 was 33.56 days (SD = 7.56).  
A series of four repeated measures ANOVAs was employed to evaluate the primary 
efficacy variables of interest: SEMCD-6 (transformed), BIPQ, PHQ-9 (transformed), and GAD-7 
scores. Study group (IG vs. TAU) was entered as a between-subjects variable, and time was 
entered as a within-subjects variable. Mauchly’s Test of Sphericity was not significant for the 
SEMCD-6, BIPQ, or PHQ-9, and so tests of within-subjects effects were interpreted with 
sphericity assumed (Field, 2013). There were no significant between- or within-groups effects, or 
significant Group X Time interactions for the SEMCD-6, BIPQ, or PHQ-9 at the .05 alpha level.  
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For the GAD-7, Mauchly’s Test of Sphericity was significant, χ
2
(2) = 10.247, p = .006, 
and the Greenhouse-Geisser estimate was less than .75, and so tests of within-subjects effects 
were estimated using the Greenhouse-Geisser estimation (Field, 2013). There was a significant 
within-subjects effect of time, F(1.497, 38.914) = 3.855, p = .041, partial η2 = .129, but no 
significant between-group effect or Group X Time interaction. Given the significant within-
subjects effects, within-subjects contrasts were evaluated for differences in GAD-7 scores 
(inclusive of all participants) across time. Contrasts revealed a significant difference between 
Times 1 and 2, F(1, 26) = 5.041, p =.033, partial η2 = .162, and between Times 1 and 3, F(1, 26) 
= 4.262, p = .049, partial η2 = .141. No significant contrasts were found between Time 2 and 3 (p 
= .720). The mean scores at respective time points were: Time1 M = 3.00 (SD = 2.54), Time2 M = 
1.96 (SD = 1.95), Time3 M = 1.85 (SD = 1.82). 
A series of four repeated measures ANOVAs was then utilized to evaluate secondary 
efficacy outcomes: STC, DIET-SE, GPAQ (transformed), and ECS scores. Mauchly’s Test of 
Sphericity was not significant for the STC, GPAQ, and ECS, and so tests of within-subjects 
effects were interpreted with sphericity assumed (Field, 2013). There were no significant 
between- or within-subjects effects, or significant Group X Time interactions for the STC, 
GPAQ, or ECS.  
For the DIET-SE, Mauchly’s Test of Sphericity was significant, χ
2
(2) = 6.463, p = .040 
and the Greenhouse-Geisser estimate was above .75, and so within-subjects effects were 
estimated using the Huyn-Feidt estimation (Field, 2013). There was a statistically significant 
main effect for Group, F(1, 26) = 6.037, p = .021, partial η2 = .188, such that collapsed across 
time, TAU scores were higher than the IG scores. Indeed, visual inspection of plotted means 
illustrated that TAU scores started higher than IG scores and remained higher over time (See 
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Table 15 in Appendix F for means over time). However, there was no significant within-subjects 
effect or Group X Time interaction. 
Reliable Change 
Reliable change cut-offs were then calculated to evaluate for changes between Time 1 
and Time 2, and between Time 1 and Time 3. Reliable change cut-offs were calculated via the 
following formula: 1.96(Sdiff), whereby Sdiff is the standard error of difference between the two 
scores (Iverson, 2018, Jacobson & Truax, 1991). Jacobson and Truax describe that Sdiff can be 
calculated by utilizing the following equation: √(2[SE]2) whereby SE is the standard error of 
measure. SE can be calculated utilizing the following equation: SD√(1-r12) whereby r12 reflects 
the test-retest reliability of the measure. While test-re-test reliability is most often utilized in this 
calculation, internal consistency is also sometimes used (Iverson, 2018; Busch, Wagener, 
Gregor, Ring, & Borrelli, 2011). Multiplying Sdiff by 1.96, yields a cut-off that can be employed 
to evaluate whether there has been reliable change on the measure. 
Per the formulas above, calculation of reliable change requires knowledge of a scale’s 
reliability (test-re-test or internal consistency) and standard deviation—see Table 6 for values 
utilized in the present study. Reliability estimates were obtained from previously published 
research. In particular, test-retest reliabilities were utilized, with the exception of the SEMCD-6 
for which only internal consistency could be obtained satisfactorily. Standard deviation estimates 
were obtained from Baseline study data (i.e., Baseline data from IG and TAU participants 
included in efficacy analyses). 
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Table 6. Reliable Change Cut-Offs 
Measure Citation Reliability SD Reliable Change “Cut-Off” 
SEMCD-6 Lorig, et al.(2001) .91 1.68 +1.40 
BIPQ Hallegraef et al. (2013) .72 10.36 +15.20 
PHQ-9 Kroenke et al. (2001) .84 4.21 +4.67 
GAD-7 Spitzer et al. (2006) .83 2.54 +2.90 
STC Paxton et al., (2011) .66 2.28 +3.69 
DIET-SE Stich et al. (2009) .83 7.63 +8.72 
GPAQ Herrmann, et al. (2013) .82 58.57 +68.88 
ECS Sallis (n.d.) .78 0.93 +1.21 
Note. SEMCD-6 = Self-Efficacy for Managing Chronic Disease Scale; BIPQ = Brief Illness Perception 
Questionnaire; PHQ-9 = Patient Health Questionnaire-9; GAD-7 = Generalized Anxiety Disoder-7; STC = Starting 
the Conversation; DIET-SE = Dieter’s Inventory of Eating Temptations-Self-Efficacy; GPAQ = Global Physical 
Activity Questionnaire; ECS = Exercise Confidence Survey 
 
Reliable change was evaluated at the group level using group means, and the cut-offs 
displayed in Table 6. For example, the IG group mean on the SEMCD-6 was 7.21 at Time 1, and 
7.86 at Time 2; the difference between these scores is .65 points which does not meet the 1.40 
cut-off, and thus does not indicate reliable change. Employing this method, neither group 
exhibited reliable change (favorable or unfavorable) on any measure between Times 1 and 2, 
and/or between Times 1 and 3. Then, data was pooled across groups to test for reliable change 
across the entire sample. Again, no reliable change was observed on any measure between Times 
1 and 2, and/or between Times 1 and 3. See Table 15 in Appendix F for group and sample means 
at each time point. 
 Reliable change for each individual was then evaluated between Times 1 and 2, and 
between Times 1 and 3. Participants required original total score data (i.e., not mean-replaced) 
for a measure at both time points in order for reliable change to be assessed. As described above, 
one TAU participant had a mean-replaced ECS total score at Time 2, and one TAU participant 
had mean-replaced total scores on every measure at Time 3. Thus, for the former participant, 
reliable change was not evaluated for the ECS from Time 1 to Time 2; for the latter, reliable 
changes were not evaluated for any questionnaire from Time 1 to Time 3.  
 50 
Changes over time were characterized as “favorable” if the differences between scores 
 met the reliable change cut-off (last column of Table 6) and indicated improvement over time. 
For example, higher scores on the SEMCD-6 indicate higher self-efficacy (a favorable outcome). 
Therefore, if a participant scored a 4 at Time 1 and an 8 at Time 3, the resulting difference of 4 
(8-4=4) meets the 1.40 cut-off and represents improvement over time (“favorable change”). 
Changes over time were characterized as “unfavorable” if the differences in scores met the cut-
off and indicated worsening symptoms. For example, higher scores on the PHQ-9 indicate higher 
level of depressive symptoms (an unfavorable outcome). Therefore, if a participant scored a 4 at 
Time 1 and a 9 at Time 3, the resulting change score of 5 falls above the 4.67 threshold and 
represents worsening symptoms (“unfavorable change”). See Table 7 for results for IG 
individuals, and Table 8 for results of TAU individuals. Cell values represent the number of 
individuals experiencing favorable change/no change/unfavorable change on each of the 
specified measures. 
Table 7. Intervention Group Reliable Change Results Calculated By Individual 













SEMCD-6 7 4 3  5 8 1 
BIPQ 0 14 0  0 14 0 
PHQ-9 1 12 1  1 13 0 
GAD-7 3 11 0  2 11 1 
STC 0 14 0  1 13 0 
DIET-SE 0 12 2  2 11 1 
GPAQ 3 9 2  3 10 1 
ECS 1 13 0  0 14 0 
Note. SEMCD-6 = Self-Efficacy for Managing Chronic Disease Scale; BIPQ = Brief Illness Perception 
Questionnaire; PHQ-9 = Patient Health Questionnaire-9; GAD-7 = Generalized Anxiety Disoder-7; STC = Starting 
the Conversation; DIET-SE = Dieter’s Inventory of Eating Temptations-Self-Efficacy; GPAQ = Global Physical 




Table 8. Treatment as Usual Group Reliable Change Results Calculated By Individual 













SEMCD-6 1 12 1  0 12 1 
BIPQ 1 13 0  1 12 0 
PHQ-9 1 13 0  1 12 0 
GAD-7 5 8 1  4 8 1 
STC 1 13 0  0 13 0 
DIET-SE 2 12 0  0 13 0 
GPAQ 0 13 1  4 8 1 
ECS 0 13 0  0 13 0 
Note. SEMCD-6 = Self-Efficacy for Managing Chronic Disease Scale; BIPQ = Brief Illness Perception 
Questionnaire; PHQ-9 = Patient Health Questionnaire-9; GAD-7 = Generalized Anxiety Disoder-7; STC = Starting 
the Conversation; DIET-SE = Dieter’s Inventory of Eating Temptations-Self-Efficacy; GPAQ = Global Physical 
Activity Questionnaire; ECS = Exercise Confidence Survey 
aThirteen out of fourteen participants had complete ECS data for Time 1—Time 2 calculation 
bThirteen out of fourteen participants had complete Time 1—Time 3 data 
 
The IG and TAU group were then compared using Fisher’s Exact Test to identify 
potential between-group differences in the likelihood of experiencing favorable change on each 
measure. Specifically, participants were coded as having either experienced favorable change or 
no favorable change over the specified time points (i.e., participants experiencing “no favorable 
change” from Time 1 to Time 2 had either experienced “no change” or “unfavorable change” 
between those time points). Results revealed that a higher proportion of IG participants as 
compared with TAU participants exhibited favorable change on the SEMCD-6 from both Time 1 
to Time 2 (p = .033), and from Time 1 to Time 3 (p = .041). Indeed, from Time 1 to Time 2, 
7/14 (50.0%) of IG participants exhibited an increase in self-efficacy scores, as compared with 
1/14 (7.1%) of the TAU group. From Time 1 to Time 3, 5/14 (35.7%) of the IG participants 
demonstrated an increase in SEMCD-6 scores, as compared with 0/13 (0%) TAU participants 
exhibiting reliable change on this measure. There were no other significant differences in 
likelihood of favorable change from Time 1—Time 2 or from Time 1—Time 3. Fisher’s Exact 
Test was then utilized to identify group-differences in likelihood of experiencing unfavorable 
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change, again with participants coded as having either experienced unfavorable change or no 
unfavorable change over the specified time points (i.e., participants experiencing “no 
unfavorable change” from Time 1 to Time 2 had either experienced “favorable change” or “no 
change” between those time points). There were no between-group differences on these 
calculations at the .05 alpha level. 
Physical Activity: Additional Analyses 
 For physical activity, in addition to computing how many individuals met the reliable 
change cut-off at given time points, we additionally examined how many individuals met a cut-
off of 150 minutes of physical activity per week. This number was derived from physical activity 
recommendations for stable CAD (Fihn et al., 2012), which suggest a minimum of 30 minutes of 
moderate-intensity aerobic physical activity, 5 days per week (which averages to 150 
minutes/week). While these recommendations are for moderate-intensity activity in particular, 
we additionally included patient-reported vigorous-intensity activity in overall weekly estimates. 
As with the reliable change analyses, only individuals with complete GPAQ data (not mean-
replaced) were included in these calculations for the relevant time points. Tables 9 and 10 
display results for IG and TAU participants, respectively. Results suggest that most participants, 
per self-report, were meeting the 150-minute/week cut-off at Baseline.  
Table 9. Intervention Group Results for Physical Activity Cut-off 
 Time 1 Time 2 Time 3 
Meeting Moderate+Vigorous Physical  
Activity Cut-off  (>150 minutes/week) 
10 11 12 
    
Not Meeting Moderate+Vigorous Physical 
Activity Cut-off (<150 minutes/week) 




Table 10. Treatment as Usual Group Results for Physical Activity Cut-off 
 Time 1 Time 2 Time 3a 
Meeting Moderate+Vigorous Physical 
Activity Cut-off (>150 minutes/week) 
12 10 9 
    
Not Meeting Moderate+Vigorous Physical 
Activity Cut-off (<150 minutes/week) 
2 4 4 
aThirteen out of fourteen participants had complete Time 3 data 
Next, changes over time were identified with regard to whether individuals met the 150 
minutes/week cut-off. In particular, participants were coded for “favorable change,” “no 
change,” or “unfavorable change” between Times 1 and 2, and between Times 1 and 3. 
Favorable change indicated that a participant switched from not meeting the 150 minute/week 
cut-off at Time 1, to meeting the cut-off at the subsequent evaluated time point. “Unfavorable 
change” indicated that the participant switched from meeting the 150 minutes/week cut-off at 
Time 1, to not meeting it at the next evaluated time point. “No change” indicated that no 
favorable or unfavorable change took place between the two time points (e.g., if a participant met 
the recommendations at Time 1 and continued to meet them at Time 2, this would be marked as 
“no change”). Results for IG participants are displayed in Table 11, and results of TAU 
participants are displayed in Table 12. Fisher’s Exact Test was then utilized to examine group-
differences in likelihood of experiencing favorable change over time, with participants coded as 
having either experienced favorable change or no favorable change (as with the reliable change 
analyses, “no favorable change” was inclusive of participants experiencing “no change” or 
“unfavorable change” between the specified time points). A second set of Fisher’s Exact Tests 
was then employed to evaluate group-differences in the likelihood of experiencing unfavorable 
change over time, again with participants coded as having either experienced unfavorable change 
or no unfavorable change over the specified time points (i.e., participants experiencing “no 
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unfavorable change” from Time 1 to Time 2 had either experienced “favorable change” or “no 
change” between those time points). 
Two IG individuals exhibited favorable change from Time 1 to Time 2, and three 
exhibited favorable change from Time 1 to Time 3. By contrast, no TAU individuals exhibited 
any favorable change from Time 1 to Time 2, or from Time 1 to Time 3; however, Fisher Exact 
Tests revealed that these between-group differences in likelihood of favorable change were not 
significant at the .05 alpha level. Similarly, Fisher’s Exact Tests were not significant for 
between-group differences in likelihood of unfavorable change from Time 1 to Time 2, or from 
Time 1 to Time 3. 
Table 11. Intervention Group Changes in Meeting Physical Activity Cut-off 
 Favorable Change No Change Unfavorable Change  
Time 1—Time 2 2 11 1 
Time 1—Time 3 3 10 1 
 
Table 12. Treatment as Usual Group Changes in Meeting Physical Activity Cut-off 
 Favorable Change No Change Unfavorable Change  
Time 1—Time 2 0 12 2 
Time 1—Time 3a 0 11 2 
aThirteen out of fourteen participants had complete Time 3 data 
Program Development and Satisfaction with Care Questionnaires 
In addition to the results from the ANOVA and reliable change analyses, information was 
gathered through the Program Development Questionnaire and Satisfaction with Care 
Questionnaires. These measures were administered at Post-Treatment for all IG participants. 
Table 13 summarizes the Program Development Questionnaire. Results reveal self-reported 
changes in lifestyle domains since starting the CLIMB program: over 70% of participants 
indicated that they made changes in terms of healthy eating, over 70% reported changes in 
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physical activity, and over 50% reported changes in stress and mood management. Results also 
provided valuable feedback that may be used to inform future iterations of brief lifestyle 
programs in outpatient cardiac care. For example, most participants reported that receiving two 
lifestyle modules was “just right” in the program. See Table 13 for additional information. 
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Table 13. Program Development Information (N=14) 
Question Results: n (%) 
 
1.  Have you made any changes regarding the way you 




Yes: 14 (100%) 
No: 0 (0%) 
 
2. To what extent do you agree or disagree with the 
following statement: 
“I have made changes in terms of healthy eating since 
starting the CLIMB program.” 
 
Strongly disagree: 0 (0%) 
Disagree: 1 (7.1%) 
Neither agree nor disagree: 2 (14.3%) 
Agree: 7 (50.0%) 
Strongly agree: 4 (28.6%) 
 
 
3. To what extent do you agree or disagree with the 
following statement: 
“I have made changes in terms of physical activity since 
starting the CLIMB program.” 
 
Strongly disagree: 1 (7.1%) 
Disagree: 1 (7.1%) 
Neither agree nor disagree: 2 (14.3%) 
Agree: 7 (50.0%) 
Strongly agree: 3 (21.4%) 
 
 
4. To what extent do you agree or disagree with the 
following statement: 
“I have made changes in terms of stress and mood 
management since starting the CLIMB program.” 
 
Strongly disagree: 0 (0%) 
Disagree: 0 (0%) 
Neither agree nor disagree: 6 (42.9%) 
Agree: 6 (42.9%) 
Strongly agree: 2 (14.3%) 
 
 
5. Would you have wanted to participate in: 
 
More modules: 4 (28.6%) 
Fewer modules: 0 (0%) 
Two was “just right”: 10 (71.4%) 
 
 
6. Would you liked to have had time to review the 
information provided in this program with behavioral 
health provider and your cardiologist jointly? 
 
Yes: 2 (14.3%) 
No Preference: 6 (42.9%) 
No: 6 (42.9%) 
 
 
7. With regard to the provided information, would you have 
preferred: to have received the information by telephone 
exclusively?   
 
Yes: 0 (0%) 
No Preference: 3 (21.4%) 
No: 11 (78.6%) 
 
 
8. With regard to the provided information, would you have 
preferred: to have received the handouts, without any 
additional contact with the behavioral health provider? 
 
 
Yes: 0 (0%) 
No Preference: 3 (21.4%) 
No: 11 (78.6%) 
 
9. What other topics would you like to be covered? Are 
there any other module topics that you would have liked 
to be available? 
 
 
Yes: 0 (0%) 
No: 14 (100%) 
 
10. To what extent do you agree or disagree with the 
following statement: 
“I would be interested in attending a peer support group for 
patients making lifestyle changes related to chronic 
disease.” 
 
Strongly disagree: 3 (21.4%) 
Disagree: 3 (21.4%) 
Neither agree nor disagree: 5 (35.7%) 
Agree: 3 (21.4%) 




Table 14 summarizes the Satisfaction with Care Questionnaire. Importantly, 100% of 
participants agreed or strongly agreed that they were satisfied with the behavioral health lifestyle 
intervention (Question 1), 92.9% (all but one person) agreed or strongly agreed that the sessions 
and material were helpful to their cardiac care (Question 3), and 71.4% reported that they felt 
more favorably toward their cardiac team following the program (Question 5).  
Table 14. Participant Satisfaction (N=14) 
Question Results: n (%) 
1. To what extent do you agree or disagree with the 
following statement: 
“I was satisfied with the behavioral health lifestyle 
intervention I received.” 
Strongly disagree: 0 (0%) 
Disagree: 0 (0%) 
Neither agree nor disagree: 0 (0%) 
Agree: 4 (28.6%) 
Strongly agree: 10 (71.4%) 
 
2. To what extent do you agree or disagree with the 
following statement: 
“I was satisfied with the behavioral health provider 
who delivered the intervention.” 
Strongly disagree: 0 (0%)  
Disagree: 0 (0%) 
Neither agree nor disagree: 0 (0%) 
Agree: 2 (14.3%) 
Strongly agree: 12 (85.7%) 
 
3. To what extent do you agree or disagree with the 
following statement: 
“The sessions and material I received were helpful to 
my cardiac care.” 
Strongly disagree: 0 (0%) 
Disagree: 0 (0%) 
Neither agree nor disagree: 1 (7.1%) 
Agree: 4 (28.6%) 
Strongly agree: 9 (64.3%) 
 
4. Would you recommend this intervention to other 
patients with coronary artery disease? 
 
Yes: 14 (100%) 
No: 0 (0%) 
5. Has your perception of your cardiac care team 
changed? 
I feel more favorably toward my team: 10 (71.4%) 
No changes: 4 (28.6%) 






Study results support the feasibility and acceptability of a brief lifestyle program for 
patients living with stable coronary artery disease. 63.5% of referred and eligible patients elected 
to participate in the study, and 83.3% of IG participants completed the program through 30-day 
follow-up—meeting study a priori feasibility criteria. Overall, such results demonstrate patient 
interest in brief programs to help maintain healthy behaviors pertinent to cardiac health. The high 
percentage of participants completing the program suggests that brief lifestyle programs 
implemented in outpatient cardiac care are promising in terms of high patient attendance, low 
attrition, and high satisfaction. Indeed, such outcomes are consistent with previous literature in 
which brief behavioral health treatment in integrated care settings has been well-attended as 
compared with non-co-located behavioral health treatment (e.g., Bartels et al., 2004). 
While most eligible patients ultimately enrolled in the study, a sizeable minority declined 
participation—most commonly due to work schedule. Although patients were made aware that 
sessions could be completed by telephone, many individuals still cited work concerns as a barrier 
to engagement. Nevertheless, our results indicate that offering telephone appointments was not 
sufficient to ensure program feasibility for all employed patients living with CAD. Appointments 
for the present study were limited to the clinic hours of 8:00 AM-5:00 PM for both in-person and 
telephone sessions. Additional options, such as evening or weekend appointments, may have 
further facilitated feasibility for patients and is recommended for future programs. 
Regarding acceptability, 100% of IG participants responded “Yes” to the question 
“Would you recommend this intervention to other patients with coronary artery disease?” —
meeting the a priori acceptability cut-off of 80%. Indeed, such results align with previous 
 59 
literature regarding patient satisfaction with integrated behavioral health services (e.g., Chen et 
al., 2006). All IG participants either agreed (28.6%) or strongly agreed (71.4%) that they were 
satisfied with the behavioral health lifestyle intervention they received. 
The modules offered in CLIMB were consistent with many lifestyle areas emphasized by 
the American Heart Association and the American College of Cardiology (Fihn et al., 2012). 
While “Healthy Eating” was the module most often selected, participants expressed interest in all 
modules except “Smoking Cessation Education”—likely because none of the participants had 
smoked a conventional cigarette within the last month. Participants were given an opportunity to 
provide feedback on the Program Development Questionnaire if there were other topics they 
would have been interested in; ultimately, no other topics were identified, further highlighting 
the relevance of the modules selected for this study. Nevertheless, other behavioral health targets 
such as sleep and medication adherence are particularly important for cardiac patients, and thus 
may serve as the basis for additional or alternate modules in future programs (Bosworth, Blalock, 
Hoyle, Czaijowski, & Voils, 2018; Hall, Brindle, & Buysse, 2018). Further, a weight 
management module may be considered for longer programs, as weight loss was a goal cited by 
many participants as they completed CLIMB. 
The most promising treatment outcome was the increase in self-efficacy for managing 
CAD (measured by the SEMCD-6) experienced by IG participants, supporting study Hypothesis 
1. Indeed, 50.0% exhibited a reliable increase in scores between Times 1 and 2, and 35.7% 
exhibited reliable favorable change between Time 1 and Time 3. By comparison, only 7.1% of 
TAU participants exhibited reliable favorable change between Times 1 and 2, and none exhibited 
reliable favorable change between Times 2 and 3. These results are encouraging given the long-
term stability exhibited by our study sample. Thus, a 3-session program was effective in 
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increasing patient confidence in managing their cardiac disease, despite having been managing 
CAD for many years. Self-efficacy is an important component of many models of health 
behavior change (e.g., Theory of Planned Behavior, Transtheoretical Model), and empirical 
evidence indeed illustrates that improvements in self-efficacy often precede meaningful changes 
in health behavior (Ajzen & Madden, 1986; Bandura, 1977, Prochaska & Velicer, 1997; Sheeran 
et al., 2016). Thus, it is possible that increasing patient confidence may have cascading health 
effects as they continue management of this long-term disease. 
While study Hypothesis 1 was supported, other study Hypotheses were not supported. In 
general, results of parametric analyses were inconclusive, and unfortunately underpowered.* One 
exception might be that the GAD-7 ANOVA revealed a significant main effect for Time. This 
result suggests that contact with a behavioral health provider in general (regardless of study 
group) may have helped contribute to reduced anxiety levels among study participants. Of 
course, results must also be interpreted within the context of meaningful change. While there was 
a statistically significant decrease in scores, changes over time did not meet the threshold for 
reliable change—possibly because participants generally exhibited low levels of anxiety, even at 
Baseline (mean Baseline GAD-7 score for study sample was 3.00, which is considered “minimal 
range”). Future research may evaluate to what extent contact with a behavioral health provider 
helps reduce anxiety among patients at varying levels of distress. For example, it is possible that 
patients in higher levels of distress will experience greater changes in symptoms. 
                                                 
*
Footnote: Power analysis using G*Power software indicated 52 participants were needed to detect between-group differences with a 
conventional large effect size of f = .40 (Cohen, 1969; Cohen 1988; Faul, Erdfelder, Buchner, & Lang, 2009) 
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One surprising result was the significant between-groups difference on the DIET-SE, 
with TAU participants exhibiting significantly higher scores collapsed across time as compared 
with IG participants. Despite randomization, TAU scores were higher than IG scores at Baseline 
by approximately five points and remained higher over time. Given the lack of Group X Time 
interaction, these between-group differences were likely a product of initial values versus 
differing rates of improvement or worsening symptoms between groups.  
Regarding the Program Development Questionnaire, 100% of IG participants reported 
that they had made changes regarding the way they manage “lifestyle and health behaviors a 
result of the intervention.” Over half of participants indicated that they had made changes in 
terms of healthy eating, physical activity, and/or mood management since starting the CLIMB 
program. Of note, these responses were obtained at post-treatment (immediately following 
Session 3) to maximize feedback in case of subsequent attrition. As a result, it is possible that 
these responses did not reflect further changes that could have occurred following the Session 3 
module (e.g., if a participant chose “Physical Activity” for Session 3, then subsequent changes 
may not have been reported until 30-day follow-up).  
Limitations and Future Directions 
While the present study provides important and promising information regarding the 
feasibility and acceptability of brief lifestyle interventions in outpatient cardiac care, the findings 
should be considered preliminary due to small sample size. For this reason, ANOVAs were 
likely underpowered to detect significant effects. Indeed, Bonferroni corrections were not 
employed, despite multiple analyses, to help avoid Type 2 error. Additionally, mean replacement 
was utilized for two individuals to impute missing that that was not missing at random. Thus, 
there is the potential that results for ANOVAs (though not reliable change analyses) were biased 
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by such estimations. While adequately powered replication studies with robust strategies for 
missing data are undoubtedly needed, it is also important to note that mean differences between 
groups were often quite small (see Table 15), and it is very possible that that even adequately 
powered ANOVAs would result in null results for some variables. 
Another limitation of the study included the age disparity between groups, despite 
random assignment. In particular, the TAU participants were younger on average as compared 
with IG participants, and it is possible that this difference confounded efficacy results. For 
example, the observed improvements in self-efficacy among IG participants could have, in part, 
been related to older age. Overall, the promising feasibility and acceptability results, in 
conjunction with the limitations of the current sample, further support the need for future larger-
N studies in this area which would allow for analyses stratified by age. 
Results must additionally be interpreted with consideration of generalizability to other 
outpatient clinics. The primary provider for the CLIMB program was a doctoral student, with a 
flexible schedule to meet participant needs within the hours of clinic operations. Thus, program 
scheduling was likely more accommodating than would be the case in a typical outpatient clinic. 
Additionally, our study sample was not necessarily representative of other outpatient clinics. For 
example, 75% of participants included in efficacy analyses had received higher education (i.e., 
beyond high school), and 46% had a masters, professional, or doctoral degree. Further, while 
many participants were former smokers, not one had smoked a conventional cigarette within the 
last month at Baseline. Most people, at least by self-report, were engaging in at least 150 minutes 
of physical activity per week. Women made up only 25% of this sample; in part, this may be 
because our study employed an age cut-off, and women are diagnosed with CAD, on average, 
later in life as compared with men. For example, one international study found that women were 
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diagnosed with MI, on average nine years after men (six years after men among the North 
American sample; Yusuf, et al. 2004). Our sample was also predominantly Caucasian. It is 
unclear to what extent our results would generalize to a more diverse population in terms of race 
and gender, and future research is needed in this regard.  
As discussed above, this study additionally had limitations regarding outcome measures. 
Unfortunately, objective data for physical activity (e.g., by accelerometers) was unavailable, and 
our eating questionnaire lacked the rigor of many others used to evaluate diet, particularly 
regarding the DASH plan (e.g., Dixon et al., 2007; Harsha et al., 2004). Other physiological 
measures related to cardiac health such as cholesterol and blood pressure readings may provide 
additional objective measurement.  
Another important limitation in measurement were demand characteristics that may have 
influenced participant responses. Importantly, the primary provider for the study administered 
study outcome measures. It is possible that participants, consciously or unconsciously, adjusted 
their responses to reflect better maintenance of healthy behaviors. Similarly, participant reports 
of satisfaction with the program may have been inflated. Some participants completed 
questionnaires by telephone, in which case responses were dictated to the research team member 
verbally rather then entered into the computer directly (e.g., during telephone appointments or 
due to technical issues). It is possible that this method of administration in particular could have 
influenced participant responses. 
 Future research may benefit from inclusion of a measure of general stress, such as the 
Perceived Stress Scale (Cohen, Kamarck, & Mermelstein, 1983) which has been utilized in 
previous cardiology research (e.g., Blumenthal et al., 2016). Average Baseline PHQ-9 and GAD-
7 scores (3.04 and 3.00 respectively) for the present study suggested minimal levels of 
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depression and anxiety among participants; however, qualitatively participants often commented 
that their levels of perceived stress were higher than such scores indicated. Inclusion of a general 
measure of stress may able to better capture changes in general distress and coping over time. 
Relatedly, future iterations of this program should be evaluated with patients who experiencing 
elevated levels of distress, whether manifesting as symptoms of anxiety, depression or difficulty 
coping with perceived stress more generally. It is possible that changes in self-efficacy observed 
in the present study will be particularly impactful for such a population. 
In general, the observed levels of depression in the current study were lower than would 
be expected given the comprehensive literature linking depression and coronary artery disease 
(e.g., Bush et al., 2005; Thombs et al., 2005). Indeed, estimates of depression among those who 
have experienced MI have often met or exceeded 20% (e.g., Bush et al., 2005; Thombs et al., 
2005). However, much of this literature has evaluated patients immediately post-MI and 
followed patients up to one-year post-cardiac event (e.g., Lauzon et al., 2003; Lesperance, 
Frasure-Smith, & Talajic, 1996). By contrast, the average time since ACS in the present study 
was 7.01 years, and many of our participants had never experienced an ACS. Future research is 
needed regarding the long-term course of depression after MI, as well as the course of depressive 
symptoms among those with stable CAD, but without history of ACS and/or revascularization. 
Indeed, it is likely that there are many variables that affect individual trajectories in depressive 
symptoms (e.g., optimism) in the years surrounding an MI (Galatzer-Levy & Bonanno, 2014). 
While the present study evaluated cigarette use and offered a corresponding Smoking 
Cessation Education module, e-cigarette use was not evaluated (though reported by one 
participant). Given the rising prevalence of e-cigarettes and concerns regarding the effects of 
nicotine on the cardiovascular system, this module may require adaptation as research emerges 
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on the relationship between e-cigarettes and heart disease (Bold, Krishnan-Sarin, & Stoney, 
2018).  
Lastly, it is important to note that study efficacy analyses may not have captured all gains 
made by participants. Some gains were reported in qualitative fashion to research members. For 
example, participants reported reduced alcohol use, elimination of whole-milk products, weight 
loss, reduced anxiety about physical activity, improved ability to cope with stress, increased hope 
for the future, and more. Such results highlight the many ways in which a brief lifestyle program 
may have a meaningful impact for patients.  
CLIMB in Clinical Practice: What’s Next? 
Overall, the implementation of CLIMB as a research protocol within a clinical setting 
was successful. Feasibility and acceptability were established, and preliminary treatment 
outcome results were promising—particularly regarding improved patient self-efficacy in 
managing their CAD.  
 With so many individuals living with CAD, it is important to consider treatments that are 
accessible to patients, and feasible with regard to clinic implementation. The brief and flexible 
nature of CLIMB lends itself to many possibilities in terms of clinical practice. For example, 
CLIMB, or similar programs, may be considered as part of a tiered approach to behavioral health 
in cardiology—such an approach has the potential to be cost-effective while providing the 
appropriate level of care to patients (Rozanski, 2014). Brief behavioral health programs may 
serve as a good “first step” for patients needing assistance with lifestyle change. Indeed, the 
present study suggests that the brief nature of CLIMB is appropriate for many patients, at 
minimum in providing and/or reinforcing important lifestyle information and helping patients to 
“get back on track” with their health goals. At minimum, those providing CLIMB to patients 
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should be licensed clinical providers (or supervised by a licensed clinical provider), given that 
cardiac populations often have significant medical and psychological comorbidities. Indeed, 
clinical training in medical settings, and with cardiac patients in particular, will aid individuals in 
working with this population most effectively. Training in health behavior change will also likely 
facilitate successful implementation of CLIMB. 
For some patients, of course, three sessions will not be sufficient to meet behavioral 
health needs. In such cases, a cardiologist may suggest patients may start with the CLIMB 
program, and then be referred to specialty providers such as a cardiac psychologist or nutritionist 
as needed. Other services, such as cardiac rehabilitation, may also be warranted. For patients 
with elevated symptoms (e.g., clinical depression) a specialty referral may be required more 
immediately. 
As a research protocol, CLIMB emphasized the individual needs of patients in various 
ways (e.g., module selection, individual health behavior feedback, personalized goals). 
Nevertheless, within the context of a research protocol there are elements of uniformity that may 
be limiting in clinical practice. For example, in the present study each patient participated in 
exactly two lifestyle modules. Perhaps increased flexibility in the number of modules patients 
receive and/or allowing patients to repeat modules would improve program effectiveness in a 
clinical setting. Of course, modules may be added or removed depending on the population of 
the clinic in which the program is implemented.  
Overall, this study suggests a bright future for integrated cardiology care teams which 
include behavioral health services. Clinical psychologists are in a unique position to develop 
treatments and programs to target modifiable and psychological risk factors for patients with 
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cardiac disease. For the psychologist looking to help patients make healthy lifestyle changes, 
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Other (describe) ______ 
 




Graduate Degree (MS, MA, PhD, JD, MD, etc.) 

















Previous Cardiac Events 
 
Have you ever been diagnosed with any of the following?        
 
Acute myocardial infarction   Y N  Number: 
 
Stable angina     Y N   
 
Unstable angina    Y N   
 
Heart failure     Y N   
 
Other cardiac event:    Y N  Describe: 
 
 
Coronary Artery Disease Treatment and Procedure History: 
 
Have you ever received the following treatment? 
 
Percutaneous Coronary Intervention  Y N # received _________ 
(Coronary angioplasty)     time since last intervention (mos): 
 
Stents      Y N # received _________ 
time since last intervention (mos):  
 
If known, specify (circle) history of:  bare metal stents drug-eluting stents both 
 
Coronary Bypass Surgery   Y N # received _________ 
        time since last surgery (mos): 
 
Cardiac Rehabilitation   Y N time since last cardiac rehab (mos): 
 





Has anyone ever recommended you to follow a specific diet for cardiovascular disease?  
 
 If so, what diet? 
 
Current medical conditions: 
  
Have you ever been diagnosed with any of the following? 
 
Hypertension (high blood pressure) 
 
Y    N 
 
Diabetes      
Y (Type 1) Y (Type 2) N  
 
Hyperlipidemia or high cholesterol?     
 
Y     N   
 
 





Aspirin      Y N 
 
Beta blockers     Y N 
 
Calcium channel blockers   Y N 
 
ACE inhibitors and/or ARB inhibitors  Y N 
 
ADP inhibitors     Y N 
 
Statin or other cholesterol-lowering drug Y N 
 
Anti-coagulants    Y N 
  




NSAIDs     Y N  
(prescribed or OTC physician-directed) 
 
List all medications (including those endorsed above): 
 
 
History of psychiatric diagnoses: 
 
Have you ever been diagnosed with or treated for depression?  
 
Y (Current) Y (Past) N 
        
Have you ever been diagnosed with or treated for anxiety?   
 
Y (Current) Y (Past) N 
 
Have you ever been diagnosed with or treated for panic attacks?  
 
Y (Current) Y (Past) N 
 
Have you ever been diagnosed with or treated for any other psychiatric disorder?  
 
Y (Current) Y (Past) N 
      
  *Specify: 
 
*Have you ever experienced any psychiatric hospitalizations?    
 
*Y   N 
 
  *Number: 
 
  *Most Recent (mos): 
 













Tobacco:  Current smoker Former smoker Never Smoked 
 






Drinking days/month (in the last month): 
 
Avg. # standard drinks on drinking days in the last month (show NIAAA image on back 
 page): 
 
*Other illicit drugs (cocaine, opiates, etc.)/prescription drug abuse (taking more or differently 
than directed, taking someone else’s medications, etc.): 
 
 





















































The healthy eating module introduces the Dietary Approaches to Stop Hypertension (DASH) 
eating plan from the National Heart, Lung, and Blood Institute (U.S. Department of Health and 
Human Services, 2003, 2006). Recommendations from the American Heart Association for 
heart-healthy eating are discussed. Participants are provided with tips for how to reduce sodium 
and fat (particularly saturated fat and trans fat) from diet. Participant barriers to implementing 
dietary changes are identified and problem-solved. At the end of the session, participants make a 
behavioral goal related to dietary change. 
 
Physical Activity 
This module focuses on physical activity guidelines provided from a task force consisting of the 
American College of Cardiology Foundation, the American Heart Association, and other medical 
associations (Fihn et al., 2012). A walking plan is introduced to help meet recommended 
guidelines. Barriers to implementing physical activity recommendations are identified and 
problem-solved. At the end of session, participants make a behavioral goal related to physical 
activity changes. 
 
Reducing Stress and Worry 
This module focuses on promoting awareness of the relationships between stress and negative 
emotions with CAD. Information is provided regarding the cognitive-behavioral therapy model, 
and the relationship between thought patterns and mood is discussed. Discussion is tailored to 
each participant’s individually identified stressors. Participants engage in an activity to challenge 
negative thought patterns. At the end of session, participants make a goal regarding monitoring 
thought processes and challenging negative thoughts. 
 
Mood Management 
This module focuses on promoting awareness of the relationships between stress and negative 
emotions with CAD. Information is provided regarding the cognitive-behavioral therapy model, 
and the importance of regularly engaging in pleasant and valued activities to promote stress and 
mood management is emphasized. Discussion is tailored to each participant’s individually 
identified stressors. At the end of session, participants make a behavioral goal regarding 
increasing engagement in pleasant and valued activities. 
 
Smoking Cessation Education 
This module focuses on the relationship between smoking and CAD. Participant smoking 
behavior is reviewed, and participants engage in a decisional balance exercise to identify costs 
and benefits of smoking vs. quitting/reducing. Participants are provided with general information 
on smoking cessation, in addition to available resources in the state of Florida for smoking 
cessation (http://tobaccofreeflorida.com/). At the end of session, participants make a behavioral 





APPENDIX D: PROGRAM DEVELOPMENT QUESTIONNAIRE 
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Please answer the following questions regarding your experience in the CLIMB program. 
 
1. Have you made any changes regarding the way you manage your lifestyle and health 
behaviors as a result of the intervention? 
 
Yes   No 
 
 Describe:  
 
2. To what extent do you agree or disagree with the following statement: 
“I have made changes in terms of healthy eating since starting the CLIMB program.” 
 
   1 = Strongly disagree  
   2 = Disagree   
   3 = Neither agree nor disagree  
   4 = Agree 
  5= Strongly agree 
 
3. To what extent do you agree or disagree with the following statement: 
“I have made changes in terms of physical activity since starting the CLIMB program.” 
 
   1 = Strongly disagree  
   2 = Disagree   
   3 = Neither agree nor disagree  
   4 = Agree 
  5= Strongly agree 
 
 
4. To what extent do you agree or disagree with the following statement: 
“I have made changes in terms of stress and mood management since starting the 
CLIMB program.” 
 
   1 = Strongly disagree  
   2 = Disagree   
   3 = Neither agree nor disagree  
   4 = Agree 
  5= Strongly agree 
 
 
5. To what extent do you agree or disagree with the following statement: 
“I have made changes in terms of smoking cessation since starting the CLIMB program.” 
 
   1 = Strongly disagree  
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   2 = Disagree   
   3 = Neither agree nor disagree  
   4 = Agree 
  5= Strongly agree 
 
6. There were five modules to choose from in this study. Which modules did you select? 
Healthy Eating 
Physical Activity 
Reducing Stress and Worry 
Mood Management 
Smoking Cessation Education 
 
 
7. Would you have wanted to participant in: 
More modules Fewer modules Two was “just right” 
 
 
8. How many sessions would have been ideal? 
 
 




Reducing Stress and Worry 
Mood Management 
Smoking Cessation Education 
 
 
10. Would you liked to have had time to review the information provided in this program 
with behavioral health provider and your cardiologist jointly? 
 
Yes  No Preference     No 
 
 
11. With regard to the provided information, would you have preferred: 
a. To have received the information by telephone exclusively? 
Yes  No Preference  No   
 
    If Yes, why: 
 
b. To have been provided with an option to receive the handouts without any 








12. What other topics would you like to be covered? Are there any other module topics that 






13. Since beginning your participation in CLIMB, have you met with another member of the 





14. Since beginning your participation in CLIMB, have you started any new treatment for 






15. To what extent do you agree or disagree with the following statement: 
I would be interested in attending a peer support group for patients making lifestyle 
changes related to chronic disease. 
 
   1 = Strongly disagree  
   2 = Disagree   
   3 = Neither agree nor disagree  
   4 = Agree 




APPENDIX E: SATISFACTION WITH CARE QUESTIONNAIRE 
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Please answer the following questions regarding your experience in the CLIMB program. 
 
1. To what extent do you agree or disagree with the following statement: 
“I was satisfied with the behavioral health life intervention I received.” 
 
   1 = Strongly disagree  
   2 = Disagree   
   3 = Neither agree nor disagree  
   4 = Agree 
  5= Strongly agree 
 
2. To what extent do you agree or disagree with the following statement: 
“I was satisfied with the behavioral health provider who delivered the intervention.” 
  
   1 = Strongly disagree  
   2 = Disagree   
   3 = Neither agree nor disagree  
   4 = Agree 
  5= Strongly agree 
 
3. To what extent do you agree or disagree with the following statement: 
“The sessions and material I received were helpful to my cardiac care.” 
 
   1 = Strongly disagree  
   2 = Disagree   
   3 = Neither agree nor disagree  
   4 = Agree 
  5= Strongly agree 
 
4. Would you recommend this intervention to other patients with coronary artery disease? 
   Yes 
   No 
 
5. Has your perception of your cardiac care team changed? 
 
1 = I feel more favorably toward my team 
2 = No changes 
3 = I feel more unfavorably toward my team 
 
6. We invite your feedback! Please provide us with any additional information that would 









Table 15. Means and Standard Deviations of Dependent Variables 
 Total Sample  Intervention Group  Treatment as Usual 
Measure Time 1 Time 2 Time 3  Time 1 Time 2 Time 3  Time 1 Time 2 Time 3 
SEMCD-6 7.64 (1.68) 8.09 (1.46) 8.14 (1.38)  7.21 (2.16) 7.86 (1.73) 8.14 (1.64)  8.07 (.90) 8.32 (1.16) 8.13 (1.13) 
BIPQ 31.86 (10.36) 29.25 (10.26) 31.13 (11.97)  30.79 (10.70) 28.64 (9.59) 30.64 (11.34)  32.93 (10.28) 29.86 (11.22) 31.62 (12.98) 
PHQ-9 3.04 (4.21) 2.18 (2.76) 2.21 (2.43)  3.21 (4.61) 2.36 (2.34) 2.57 (2.62)  2.86 (3.94) 2.00 (3.21) 1.85 (2.25) 
GAD-7 3.00 (2.54) 1.96 (1.95) 1.85 (1.82)  3.07 (2.37) 2.00 (1.62) 1.93 (1.73)  2.93 (2.79) 1.93 (2.30) 1.77 (1.97) 
STC 5.32 (2.28) 4.86 (2.24) 4.89 (2.04)  5.64 (2.68) 5.29 (2.46) 4.79 (2.36)  5.00 (1.84) 4.43 (1.99) 5.00 (1.75) 
DIET-SE 28.50 (7.63) 29.57 (8.19) 31.02 (7.82)  25.79 (6.34) 25.57 (7.63) 28.43 (8.98)  31.21 (8.06) 33.57 (6.82) 33.62 (5.65) 
GPAQ 63.56 (58.57) 65.75 (63.68) 89.52 (79.14)  58.61 (57.53) 73.83 (74.29) 84.87 (71.59)  68.51 (61.34) 57.67 (52.56) 94.18 (88.53) 
ECS 3.91 (.93) 4.07 (.65) 4.03 (.73)  3.77 (.91) 4.07 (.57) 3.87 (.80)  4.05 (.96) 4.07 (.74) 4.18 (.64) 
Note. SEMCD-6 = Self-Efficacy for Managing Chronic Disease Scale; BIPQ = Brief Illness Perception Questionnaire; PHQ-9 = Patient Health Questionnaire-
9; GAD-7 = Generalized Anxiety Disoder-7; STC = Starting the Conversation; DIET-SE = Dieter’s Inventory of Eating Temptations-Self-Efficacy; GPAQ = 
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